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HSQC: Heteronuclear Single Quantum Coherence 
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Each biomolecule in a living organism needs to adopt a specific three-
dimensional conformation to function properly. Function itself is usually 
achieved by specific interactions between biomolecular units. Structural 
knowledge at atomic level of biomolecules and their interaction is important to 
understand the mechanisms leading to biological response and to develop 
strategies to interfere with them when necessary. 
Antibodies are molecules of the immune system playing an ever more 
prominent role in basic research as well as in the biotechnology and 
pharmaceutical sectors. Characterizing their region of interaction with other 
proteins (epitopes) is useful for purposes ranging from molecular biology 
research to vaccine design. 
During my PhD studies I used a combination of solution NMR mapping, 
molecular biology and computational docking to provide a structural and 
biophysical characterization of new neutralizing antibodies from Dengue 
virus recovered subjects, comparing the binding of the same antibody to the 
four Dengue serotypes and the binding of different antibodies to the same 
serotype. We were able to rationally mutate an antibody to first alter its 
selectivity for different viral strains and then increase its neutralization by 
~40 folds. For the first time, this was achieved without the availability of an 
x-ray structure. 
In a second sub-project, I investigated the interaction of the chemokine 
CXCL12 with the chromatin-associated protein HMGB1, confirming their 
direct interaction (only proposed but never proved before) and providing a 
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structural explanation for the HMGB1 dependent increase of CXCL12 
cellular activity. High profile publications resulted from the two above 
projects. 
The above mentioned projects relied heavily on solution NMR spectroscopy, 
which is ideally suited to the atomic level characterization of intermolecular 
interfaces and, as a consequence, to antibody epitope discovery. Having 
provided a residue-level description of a protein-protein interface by NMR, we 
subsequently used this experimental information to guide and validate 
computational docking experiments aimed at providing a three dimensional 
structure of the protein-protein (or antibody-protein) complex of interest. In 
collaboration with other members of my research group I validated the use of 
NMR and computational simulations to study antibody-antigen interactions, 




























Antibodies play an ever more prominent role in basic research as well as in the 
biotechnology and pharmaceutical sectors. Characterizing their epitopes, i.e. 
the region that they recognize on their target molecule, is useful for purposes 
ranging from molecular biology research to vaccine design and intellectual 
property protection.  
Solution NMR spectroscopy is ideally suited to the atomic level 
characterization of intermolecular interfaces and, as a consequence, to epitope 
GLVFRYHU\ +HUH LW¶V LOOXVWUDWHG how NMR epitope mapping can be used to 
rapidly and accurately determine protein antigen epitopes. The basic concept 
is that differences in the NMR signal of an antigen free or bound by an 
antibody will identify epitope residues. NMR epitope mapping provides more 
detailed information than mutagenesis or peptide mapping and can be much 
more rapid than x-ray crystallography. Advantages and drawbacks of this 
technique are discussed together with practical consideration. 
 
Introduction 
Antibodies are proteins capable of recognizing their target molecule, called 
antigen, with high affinity and specificity. They play an ever more prominent 
role in basic research as well as in the biotechnology and pharmaceutical 
sectors1. Antigens are recognized through atomic interactions between up to 
six highly variable antibody loops, called antigen binding loops, and the so-
called epitope, which is the region of the antigen contacted by the antibody. 
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Generally speaking, characterizing epitopes will improve our understanding of 
the molecular basis for antibody-antigen recognition. This in turn could allow, 
in the long run, altering existing antibodies or designing new ones with desired 
properties. Discovering the epitope of a given antibody also has more short 
term purposes. If antibody binding affects a protein function, then the epitope 
may indicate which part of the protein is responsible for such function. The 
epitope of an antibody capable of blocking the binding of a protein to cells, for 
instance, may reveal the receptor binding site of the protein antigen. 
Furthermore, including a detailed epitope description in a patent is expected to 
strengthen the protection of intellectual property2. Epitope discovery is also 
highly relevant for vaccine design. Most vaccines act by injecting an antigen 
in an individual and generating an antibody response. Using full pathogens, 
e.g. a virus, as vaccines has two main disadvantages: the pathogen needs to be 
suitably inactivated; the full pathogen may have regions that generate 
ineffective antibodies. For instance, the seasonal influenza vaccine contains a 
highly variable region that generates antibodies incapable of protecting against 
future circulating influenza strains. One strategy to overcome these problems 
is to look for highly effective antibodies3, find out what their epitope is and 




Mapping an antibody epitope  
Since the epitope is the region of an antigen that interacts with the antibody, a 
three-dimensional structure of an antibody/antigen complex, usually obtained 
by x-ray crystallography, provides the most thorough description of epitopes. 
An atomic structure, in fact, allows the observation of specific intermolecular 
contacts.  
X-ray structures, however, are often laborious to obtain and not always 
available. On the other hand, epitope prediction by computational algorithms 
is fast and affordable but has not yet reached widespread accuracy. In the case 
of protein antigens, other techniques like peptide mapping and site directed 
mutagenesis provide important clues to an antibody epitope but have 
significant limitations. In peptide epitope mapping short portions of a protein 
sequence are synthesized and then tested for binding to an antibody. A 
positive result indicates that the peptide sequence is indeed part of the 
antibody epitope. Antibody recognition, however, often requires the presence 
of a well-defined three-dimensional structure in the epitope (so-called 
conformational epitopes). It is often not trivial to reproduce such structure in a 
peptide library. In these circumstances it is impossible to know if a negative 
result implies that the peptide sequence is not part of the epitope or that, 
instead, the proper atomic structure is missing. Finally, if mutagenesis of 
single protein residues prevents antibody binding, then it may be assumed that 
such residue is part of the epitope, although allosteric effects need to be taken 
into consideration. The main problem with this approach is that it is difficult 
to obtain information on all residues forming the epitope.  
14 
 
+HUH LW¶V GHscribed how solution NMR spectroscopy can be used to 
characterize antibody epitopes. The strategy is faster than x-ray 
crystallography, is effective for conformational epitopes and provides a more 
thorough description than peptide mapping or site directed mutagenesis. 
Advantages and disadvantages are illustrated below, together with some 
practical considerations. Although the description focuses on protein antigens, 
similar considerations are valid for other molecules. 
 
NMR epitope mapping  
Solution NMR spectroscopy is particularly suited to the characterization of 
intermolecular interactions, including the determination of antibody epitopes. 
The NMR signal, in fact, is exquisitely sensitive to the local chemical 
environment. When an intermolecular complex forms, the chemical 
environment of interface atoms changes as they get close to the atoms of the 
interacting partner, and so does their NMR signal. By comparing the NMR 
spectrum before and after complex formations, interface atoms can be 




Figure 1: Schematic representation of an NMR epitope mapping experiment. 
Residues A and B of a 15N labelled protein antigen (left) generate a single 
peak in a 15N-HSQC experiment, schematically shown at the top. Upon 
antibody binding (right), epitope residues experience a different chemical 
environment and their NMR signal changes, as shown for residue B in the 
scheme. The antibody is unlabeled and its signals do not appear in 15N-
HSQCs. By comparing the NMR spectrum of the antigen free and in complex 
with the antibody, epitope residues whose signal is affected by binding can be 
identified. 
Here we illustrate the characterization of protein epitopes for simplicity, but 
similar considerations are valid for other molecules. 
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In a 15N-HSQC experiment4 the backbone NH group of each protein residue 
















Figure 2: 15N-HSQC spectra of an antigen derived from Dengue virus either 
free (blue) or in complex (red) with a full antibody (left), with a Fab fragment 
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(center) or with a scFv fragment (right). A schematic representation of the 
molecules involved is shown in the lower right corner. Each peak correspond 
to a single antigen residue in these experiments. Signal intensity increases and 
broadening decreases when analyzing smaller antibody fragments. Changes in 
the position of some peaks upon complex formation can be discerned. 
The position of these signals is so sensitive to the protein conformation that 
15N-HSQC spectra are often referred to as protein fingerprints. Protein 
labelling with 15N (see below) is required because the naturally occurring 
nitrogen isotope, 14N, gives complicated NMR spectra (I=1). 
The idea behind NMR epitope mapping, schematically illustrated in figure 1, 
is to: 
1) Record a spectrum of the free, labeled protein antigen. 
2) Add unlabeled antibody and record a HSQC of the complex. Since the 
antibody is not labelled, its residues do not produce an NMR signal and thus 
do not appear in the spectrum.  
3) Overlay and compare the spectra of the antigen free and in complex with 
the antibody. If a signal changes position it means that the chemical 
environment of the residue generating it has changed; in other words, the 
residue is affected by antibody binding and is likely to belong to the epitope. 
The list of all antigen residues whose signal changes upon antibody addition 
provides a full description of the epitope. 13C-HSQCs may be used instead of 
15N-HSQC. However, since the former has one peak for each CH group in the 
labelled molecule and since there are many more CHs than NHs in a protein, 
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13C-HSQCs are often marred by spectral overlap and are consequently less 
informative. In case of spectral overlap, in fact, it is often difficult to discern if 
peaks change position upon complex formation and to distinguish which of the 
residues with overlapping signal is affected. Due to similar considerations, 
15N-HSQC spectra of proteins with many residues are more difficult to 
analyze. Generally speaking, because of spectral overlap proteins larger than 
200 residues may not be suitable to NMR epitope mapping without selective 
labeling. This problem can be alleviated by labelling only specific amino acids 
in the protein, for instance all tyrosines. This is usually achieved by including 
appropriately labelled nutrients in the growing media during protein 
expression5,6. Alternatively, protein segments of a few contiguous residues can 
be selectively labelled7-9. Large proteins present a second challenge to NMR 
epitope mapping. The intensity of the NMR signal, in fact, decreases at 
increasing molecular weight5,10-12. The signal arising from large proteins (or 
protein complexes) may be undetectable. However, TROSY versions of 
HSQC experiments can alleviate the problem and provide a signal even for 
large molecules13. The decision to run simple HSQCs or their TROSY 
equivalent should be taken on a sample by sample basis, since one or the other 
may offer better signal intensity according to specific sample conditions. 
Protein labelling with deuterium (2H), which may complicate sample 
preparation, is required for optimum TROSY performance. When conducting 
NMR epitope mapping studies we typically acquire both a quick HSQC and 
TROSY experiment, evaluate which is better and then run a long experiment 
with the chosen option. Both spectral overlap and the lack of sensitivity at 
increasing molecular weight can be alleviated by the use of high field NMR 
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spectrometers commonly available today. We have successfully performed 
NMR epitope mapping experiments on a 600MHz spectrometer in some cases, 





Which is which? Protein assignment  
Comparison of 15N-HSQC experiments of a protein antigen free and in 
complex with an antibody identifies NMR signals affected by antibody 
binding and therefore likely to belong to residues that are part of the epitope. 
In order to map the epitope on the protein primary sequence or three-
dimensional structure we need to know which signal belongs to which residue. 
A detailed description of this process, called protein assignment, goes beyond 
the scope of this thesis14-16. Suffice to say that assignment requires collection 
and analysis of several different NMR experiments, usually obtained from 
proteins labelled with both 15N and 13C. Assignment may take as little as a 
week, as long as a few years or be altogether impossible to obtain. Size of the 
protein, sample behaviour (e.g. propensity to aggregate, lack of stability over 
time etc) and protein secondary structure may all affect the difficulty and thus 
the time required to assign a protein. Although each case is different, proteins 
with less than 120 residues are often trivial to assign and proteins above 200 
residues become complicated and require longer time and/or strategies like 
selective labelling. An unsupervised search of the Protein Data Bank shows a 




Figure 3: Distribution of molecular weights of the NMR structures deposited 
in the PDB. Colors indicate molecular weight ranges (kDa) as shown in the 
legend. The number of structures for any given rage is indicated in the chart. 
The vast majority of these have molecular weight below 20kDa and only 29 of 
them above 40kDa. It is important to note that structure determination is much 
more complicated than assignment alone17,18; nonetheless, the data provides an 
idea of what has been achieved so far with NMR.  
Assignment of the free antigen is essential but formal NMR assignment of the 
antigen in complex with the antibody, which is much more difficult to obtain, 
is not strictly necessary unless a quantitative analysis is desired (see below). If 
the signal of a given residue changes position (or disappears) upon complex 
formation, then we know that the residue is affected by antibody binding even 
if we do not know its exact position in the spectrum of the complex. In other 
words, it is not necessary to know where a peak moves upon complex 
formation, it suffices to know that it is not in the position it had in the 
22 
 
spectrum of the free antigen. Complex assignments can be estimated by 
simple comparison to the free antigen spectra. When changes are small it is 
usually trivial to pair each peak in the complex to its free counterpart. The 
larger and more numerous the changes, the less reliable this approach 
becomes. If a protein changes its structure upon complex formation, for 
instance, it may be impossible to assign it by comparison. If complex 
assignment is only available by comparison to the free spectra and ambiguities 
DUH SUHVHQW RQH SRVVLELOLW\ LV WR FRQVLGHU WKH ³PLQLPXP VKLIW GLIIHUHQFH´19. 
The amount of chemical shift change is defined as the difference between a 
peak in the free spectrum and its closest peak in the bound state. This 
guarantees that the entity of the chemical shift change is equal or larger to the 
one set in the analysis, but it is not overestimated. Once assignment is 
available, directly or from a public database20, epitope mapping of any 
antibody interacting with the same antigen can be obtained in a matter of 
hours. HSQC experiments on the antigen free and in complex with one 
antibody require 24 hours at most. Comparison of the two spectra and 
identification of the NMR signals affected by antibody binding can be 
completed in a couple of days. Having the assignment, mapping those signals 





What is a significant change in NMR signal? Define residues affected by 
antibody binding  
We can identify epitope residues by detecting changes in their NMR signal 
upon formation of the complex with an antibody. Although the concept is 
simple, a precise definition of what is considered a significant change might 
not be. How much does an NMR peak need to change position to be 
considered different is a question open to subjective interpretations. When 
analyzing quantitatively a 15N-HSQCs, one possibility is to measure the 
distance between a peak position in the free and bound form in both the 
nitrogen and proton dimension and combine the two terms in a formula like 
>¨1+2¨15N/10)2]1/2 (different formulas may be used). This generates a 
³FKHPLFDO VKLIWSHUWXUEDWLRQ LQGH[´-&63WKH WHUP³FKHPLFDO VKLIW´ LQGLFDWHV
the position of the NMR signal). The difference in 15N chemical shift is 
divided by 10 to compensate the larger frequency range. It is then possible to 
average the values off all antigen residues and consider the signal of a given 
residue significantly different upon complex formation if its chemical shift 
perturbation index is more than one standard deviation away from the average. 
This method may work well for small, well behaved protein complexes. In our 
experience, however, it is often not suitable to large antibody/antigen 
complexes marred by spectral overlap, signal broadening and other 
complications. One alternative is to plot the chemical shift perturbation index 




Figure 4: Quantitative analysis of an NMR epitope mapping experiment. The 
Chemical Shift Perturbation index (CSP, see main text) is plotted for each 
antigen residue. Regions with higher CSP are identified and an arbitrary 
threshold is set (red line). Antigen residues with CSP above the threshold are 
considered to be affected by antibody binding. On the bottom, these residues 
are colored in red and orange on the structure of an antigen (blue) in complex 
with the antibody (green). They define an epitope region compatible with the 
dimension of an antibody binding site. 
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Similar plots often reveal the presence of contiguous residues whose signal is 
affected by complex formation and often allow setting an arbitrary threshold: 
if a residue has a perturbation value above the threshold it is considered 
affected by antibody binding. See below for further details on how to set the 
threshold. Due to the complexity of the system, we prefer to adopt a more 
qualitative approach whose flexibility offers better results in antibody/antigen 
complexes, in our experience. We divide the 15N-HSQC peaks, and thus the 
protein residues, in four classes: 1) large changes: residues whose position 
shifts by more than 0.4ppm in the nitrogen or 0.04ppm in the proton 
dimension and that are clearly visible in the NMR spectrum (no overlap or 
other uncertainties); slightly different threshold values might be set on a case 
by case basis.  
2) Small changes: residues whose signal changes by less than the values 
above.  
3) No changes: residues whose NMR signal does not change upon complex 
formation.  
4) Unknown: the effect of antibody binding on these residues cannot be 
determined due to lack of assignment, spectral overlap or other problems. 




Figure 5: 15N-HSQC peaks of an antigen free (blue) or in complex with an 
antibody (red). Differences between free and bound spectra indicate that the 
residues generating the peaks shown are affected by antibody binding and 
likely part of the epitope. Examples of large, small or no changes upon 
complex formation are shown. 
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It should be noted that the magnitude of the NMR change (large/small) is not 
directly correlated to the distance of a given residue to the antibody. Although 
the effect is not detected at distances larger than approximately 7Å, a change 
in NMR signal depends on the magnetic properties of the local environment 
surrounding a given chemical group. There is no simple equation correlating 
the amount of change in the NMR signal to the distance between two residues 
on interacting molecules. Proximity of an aromatic ring, for example, 
generally provokes larger changes than equal distance to a non-aromatic ring 
due to ring current effects having a strong impact on the nearby magnetic 
properties21. Having divided the antigen residues in the above four classes, we 
PDSWKRVHZLWK³ODUJHFKDQJHV´RQWKHDQWLJHQVWUXFWXUH7KH\XVXDOO\IRUPD
well-defined, contiguous region compatible with the known dimensions of 
antibody binding sites. Residues in the ³VPDOOFKDQJHV´FODVVDQGUHVLGXHVWKDW
apparently have large changes but are marred by some uncertainty like partial 
spectral overlap are included only at a second stage and only if there is clear 
structural evidence that they are part of the NMR derived epitope. For 
LQVWDQFH D ³VPDOO FKDQJH´ UHVLGXH VXUURXQGHG LQ WKH WKUHH-dimensional 
VWUXFWXUHE\³ODUJHFKDQJHV´LVXVXDOO\DGGHGWRWKHHSLWRSH:HWUHDW³VPDOO
FKDQJH´ UHVLGXHV RQ WKH IULQJH RI WKH HSLWRSH GHILQHG E\ WKH ODUJH FKDQJHV
with caution and include them only if there is other evidence justifying it, for 
LQVWDQFH IURP PXWDJHQHVLV RU FRPSXWDWLRQDO VLPXODWLRQV ,VRODWHG ³VPDOO
FKDQJHV´ UHVLGXHV PD\ DSSHDU RQ UHJLRQV RI WKH SURWHLQ FOHDUO\ RXWVLGH WKH
well-defined epitope, for example on the face of the protein antigen opposite 




epitope, not even if they are in the middle of a clearly defined epitope. 
Although the initial analysis should strictly rely on undisputed NMR 
information to avoid bias, the process becomes iterative and structural 
considerations are used to help resolve ambiguities in the NMR spectra. A 
similar approach is standard for NMR structural determination besides 
mapping experiments. The outlined approach works well in our experience 
and its accuracy was validated by x-ray structures in at least three cases22-24, 
but it is qualitative and has some subjective terms. For these reasons, it is 
important to be conservative in the choice of residues to be included. Defining 





The NMR peaks of antigen residues affected by antibody binding change 
position upon complex formation. Epitope signals, however, may also 
disappear upon binding. This is a consequence of ³FKHPLFDO H[FKDQJH´25, 
whose thorough description goes beyond the scope of this thesis. Briefly, an 
epitope residue alternating between free and bound state may  
i) Generate two NMR signals, one corresponding to the free state and a 
different one for the bounGVWDWH7KLVLVFDOOHG³VORZH[FKDQJHUHJLPH´ZLWK
slow referring to the timescale of NMR experiments, and is usually expected 
for high affinity antibody complexes with slow dissociation rates. This 
situation is usually simple to analyze in NMR epitope mapping.  
LL,Q³IDVWH[FKDQJH´HSLWRSHUHVLGXHVDOWHUQDWHEHWZHHQIUHHDQGERXQGVWDWH
before the NMR observation is completed; the result is a single signal in a 
position related to the average of the positions in the two states. This average 
position is different from the free state and can therefore be discerned in 
mapping experiments. 
LLL 7KH 105 VLJQDO RI UHVLGXHV LQ ³LQWHUPHGLDWH H[FKDQJH´ EURDGHQV DV D
consequence of their alternating between free and bound state. The effect can 
be so profound to make the signal of interface residues disappear below the 
noise. If certain antigen residues disappear upon complex formation, therefore, 
it might be tempting to conclude that they belong to the epitope. Although this 
may be the case, further considerations complicate the issue and recommend 
caution. The NMR signal, in fact, becomes broader not only because of 
chemical exchange but also due to increasing molecular weight. The effect, 
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significant in epitope mapping due to the large size of antibodies, is identical 
for all antigen residues: upon antibody binding the molecular weight of the 
observed species increases and all NMR peaks become broader regardless of 
them being part of the epitope, leading to partial or even complete loss of 
signal (compare the peak intensity of free and bound antigens in figure 2). To 
further complicate matters, signal broadening depends also on the structural 
flexibility of individual residues. Proteins have regions with different mobility. 
Beta strands in the protein core, for instance, are usually more rigid than 
protein loops. The combination of these factors may result, for example, in the 
signal of a strand residue disappearing upon complex formation due to 
broadening while a flexible loop residue remains visible. This depends strictly 
on local protein mobility and it would be erroneous to suggest that one of the 
two residues is part of the epitope. Overall, evaluating broadening effects in 
NMR epitope mapping is complicated and may easily lead to inaccurate 
epitope assignment. Even more so since it is often impossible to obtain a 
quantitative analysis of the broadening effects due to the poor spectral quality 
typical of antibody/antigen complexes. There are instances when including in 
the epitope a residue whose signal disappears upon complex formation might 
be appropriate, but they are rare in our experience. In the rare cases when we 
might use these considerations, we only do so towards the end of the iterative 




Does every affected residue belong to the epitope? Allosteric effects  
Antigen residues whose NMR signal changes upon addition of an antibody 
are, indeed, affected by antibody binding. The NMR change, however, only 
reflects a difference in local chemical environment. This can derive from a 
direct contact with the antibody, meaning that a residue is part of the epitope, 
or from allosteric effects. If antibody binding to one site (epitope) provokes 
structural changes in a second site, then residues in this second site will have 
NMR chemical shift changes as well. Allosteric effects cannot be 
distinguished by NMR chemical shift perturbation experiments alone. 
Structural considerations and other experimental evidence should be sought to 
clarify the issue. Dedicated NMR experiments can help to differentiate direct 
antibody contact from allosteric effects but they have disadvantages over 
simple HSQC mapping both in term of sensitivity and sample preparation. In 
cross-saturation experiments, for instance, the antigen needs to be uniformly 
labelled with 15N and 2H while the antibody remains unlabeled26. The antibody 
protons of aliphatic sidechains are then saturated by an NMR pulse which 
affects them and the protons spatially close to them. The NH groups of the 
antigen close to the saturated antibody protons are thus affected and their 
NMR signal broadens, whereas long range allosteric effects have no impact. 
This allows identification of epitope residues directly in contact with the 
antibody without interference from allosteric effects. There are two main 
problems with cross-saturation experiments. If deuteration of the antigen is not 
complete, the remaining antigen protons will be saturated and antigen residues 
that are close to them, and not to the antibody, will be affected, leading to 
incorrect epitope determination. Furthermore, NMR cross-saturation 
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experiments are less sensitive than HSQC experiments, leading to lack of 
signal in the case of large antibody-antigen complexes. Finally, the conditions 
required to achieve complete deuteration are toxic for Escherichia coli or 
similar expression organisms, increasing the difficulty in obtaining sufficient 
amounts of the required protein sample. Deuterium exchange NMR studies are 
another strategy to avoid detecting allosteric effects. If a 15N labelled protein is 
dissolved in D2O, NH backbone protons exchange with the solvent and 
become ND. Since deuterium does not produce an NMR signal at the 
frequencies monitored in a 15N-HSQC, their peaks disappear. Interface 
residues in an antibody/antigen complex, instead, may be buried and not 
accessible to the solvent; their NH groups, therefore, would not exchange with 
the solvent and remain detectable in a 15N-HSQC. Comparison of the spectra 
of the free and complexed antigen dissolved in D2O allow identification of 
residues that are shielded from solvent exchange only in the complex and are, 
therefore, likely to belong to the antigen/antibody interface or, in other words, 
be part of the epitope. Residues located in the protein core are easily identified 
because they are protected from solvent exchange both in the free and 
complexed antigen. The main drawback of this approach is that an 
antibody/antigen complex must be formed in solution, then ideally lyophilized 
and re-dissolved in D2O. Not all antibody/antigen samples tolerate this harsh 





Antibodies are molecules of approximately 150kDa that include two identical 
antigen binding sites. Their large size is often detrimental to NMR 
investigation for reasons illustrated above. One option to reduce their size is to 
digest them to so-called Fab fragments; these are approximately 50kDa 
molecules with only one antigen binding site. Their production requires a 
straightforward enzymatic digestion27 and purification step and commercial 
kits are available for this. Drawbacks of this procedure are the costs, both for 
reagents and due to the loss of material, and the fact that Fab fragment lack 
avidity effects that may be important for antibody function. Avidity indicates 
the ability of a single antibody molecule to bind the same antigen with both its 
binding sites at the same time, usually leading to increased affinity. However, 
in our experience the smaller molecular weight of Fab fragments offer a 
significant sensitivity advantage in NMR epitope mapping studies, so we 
prefer working on Fab rather than full antibodies whenever possible. The 
antibody size can be further reduced if it is produced as a single chain version 
of its variable region. This fragment (scFv) contains one antigen binding site 
and is approximately 25kDa28. scFv are not natural molecules and need to be 
engineered and produced in Escherichia coli or other systems. This is 
inconvenient (and often impossible due to refolding and aggregation 
problems) when they are derived from a full, natural antibody. However, 
artificial methods for antibody discovery and optimization like yeast display 
libraries29 generate scFv molecules. The small molecular weight of scFv 





i) These molecules are prone to aggregation that may actually increase their 
apparent size to more than that of Fab fragments and  
ii) Their production if often laborious and far from guaranteed. NMR epitope 
mapping experiments on full antibody, Fab fragment and scFv fragment are 
shown in figure 2. 
As previously stated, we find it most advantageous to perform NMR epitope 
mapping using 15NHSQC experiments. These experiments are very sensitive, 
which is important in large antibody/antigen complexes, are simple to analyze 
and yet provide a thorough residue-level description of the epitope. We 
typically run them for less than an hour on the free antigen and for 16/24 hours 
on the antibody/antigen complex, in order to increase the signal to noise ratio. 
We usually avoid other labelling options for simplicity of sample preparation. 
Finally, just as in any NMR experiment, buffer conditions, temperature etc 
need to be screened to avoid aggregation or other problems, and NMR 
parameters need to be optimized for sensitivity. 
Conclusions  
Solution NMR spectroscopy is ideally suited to the characterization of 
intermolecular interfaces, including antibody/antigen complexes. NMR 
chemical shift mapping provides a detailed description of the binding footprint 
of one molecule over another. Comparing the NMR spectrum of an antigen 
free and in complex with an antibody allows the determination of epitope 
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residues. The results are accurate and as detailed as those obtained from x-ray 
crystallography, as it was shown when NMR mapping of a TCR/pMHC 
complex (molecules very similar to antibody/antigen complexes) was 
validated by a later x-ray structure24. The NMR binding footprint of the TCR 
over the pMHC, equivalent to an antibody epitope, is in agreement with the 
















Figure 6: Comparison between an intermolecular interface determined by 
NMR mapping and x-ray crystallography (TCR/pMHC complex, which share 
many similarities with antibody/antigen complexes (Varani, Bankovich et al. 
2007). The MHC structure is shown in grey, surface representation. MHC 
residues whose NMR signal is affected by TCR binding are shown in red on 
the top; MHC residues within 5A of the TCR in the x-ray structure are shown 
in green in the middle. Interface residues according to both NMR and x-ray 
are shown in yellow on the bottom. The rightmost structure shows good 
agreement between NMR and x-ray mapping. Some short range allosteric 
effect can be seen in the top right, red residues in the comparison picture. 
In other works, the results of NMR epitope mapping were used to greatly 
increase the accuracy of computational docking, providing a three-
dimensional atomic structure of the antibody/antigen complex. Roughly 
speaking, information on the NMR derived epitope is either used as a 
constraint to guide the structure calculation algorithm30-32, possibly with other 
information that can help to orientate the components of a multi-molecular 
complex33, or at the end of the computational simulation to filter out models 
that do not agree with the experimental epitope34,35. The resulting structures 
were sufficiently accurate to allow rational modifications of an antibody, 
altering its selectivity and increasing its viral neutralization properties by up to 
40 folds36. Such rational engineering is often thought to require an x-ray 
structure. Although x-ray is obviously better at structure determination, NMR 
mapping offers comparable results in a fraction of the time for epitope 
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characterization. Once NMR assignments are available for the antigen several 
different antibodies can be rapidly mapped, typically requiring a couple of 
days per antibody. NMR epitope mapping also has a clear advantage over 
peptide mapping and site directed mutagenesis, since it provides a complete 
description of the antigen residues contacted by the antibody which is very 
difficult to obtain by these other techniques. The disadvantages of NMR 
epitope mapping include the fact that the antigen needs to be labelled with 
NMR active nuclei (typically 15N). It is thus necessary to express the antigen 
in Escherichia coli (more seldom yeast), which is not always possible. 
Furthermore, large antigens present a challenge for NMR, due to both spectral 
overlap and signal broadening at increased molecular weight leading to loss of 
sensitivity. Selective labelling of specific antigen residues, advanced 
acquisition techniques like TROSY and the use of 15N-HSQCs, probably the 
simplest and most sensitive multidimensional NMR experiment, somehow 
alleviate these limitations, which nonetheless remain significant in some cases. 
Finally, NMR assignment of the antigen, i.e. knowing which NMR signal 
corresponds to which antigen residue, is necessary. Assignment can be a 
trivial process of a few days or a difficult task requiring several months and 
complex strategies for selective labelling. If assignment is not available, NMR 
epitope mapping can still be useful to map the relative position of multiple 
antibodies. In a sort of residue level cross-competition experiment, it is 
possible to see if the same peaks (corresponding to antigen residues) are 
affected by binding of different antibodies. NMR epitope mapping is a rapid 
and accurate tool for the characterization of antibody/antigen complexes. So 
far there are relatively few examples of using high resolution NMR 
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spectroscopy to determine antibody epitopes and most involve small peptides 
rather than full protein antigens35-42 but we are strongly convinced that NMR 
epitope mapping is a valuable tool for the detailed structural characterization 




















Molecular docking is a popular and useful tool in the drug design; Ligand 
binding is the key step in enzymatic reactions and, thus, for their inhibition. 
Therefore, a detailed understanding of interactions between small molecules 
and proteins may form the basis for a rational drug design strategy43-46, as well 
as a better understanding of interaction between antibody and antigen through 
specific atomic interactions between the antibody and the region of the antigen 
(Ag) that it recognizes (epitope) is expected to accelerate vaccine 
development, since most current vaccines are based on the generation of 
neutralizing antibody responses. If we understand the structural rules 
governing Ab-Ag interactions in a given virus, for instance, then we have the 
molecular basis to attempt to design and synthesize new epitopes to be used as 
vaccines, optimize the antibodies themselves for passive immunization or 




The best way to study atomic interaction is to obtain the three-dimensional 
structure of antibody-antigen complexes. Traditionally, this is achieved by X-
ray crystallography technique, an often long and laborious process with high 
failure rate. Thanks to advances in algorithms and processing power, now we 
are able to use computational techniques for the structural characterization of 
intermolecular complexes. 
Computational docking is the process of predicting the structure of a complex 
starting from the separated structures of its individual components47, it is 
emerging as a fast and affordable technique for the structural characterization 
of antibody-antigen complexes and protein-protein complexes. Some of the 
computational docking predictions can be very accurate, but the algorithm 
often fails to discriminate them from inaccurate solutions. It is of paramount 






The ability of the docking prediction is to sample many state of a complex, 
determining the free energy, called score, for each of them, so the predicted 
structures having lower free energy are the most likely realistic three-
dimensional structure for the complex, considering the hypothesis that the 
structure of a complex is the lowest free energy state accessible to the 
system48. 
In a typical docking protocol, the structures of the antigen and antibody are 
separated by approximately 25 Å and subsequently brought together by the 
chosen algorithm. Usually the bigger structure of the 2 partners is fixed in the 
space and the smaller one is moved in the direction of the previous one with 
small movements, each new movement create a new energy state (score) for 
the computational complex. This is an iterative process continuing up to find 
the lowest possible score for the computational complex. This iterative process 
generate thousands of computational complex structures each one with a 
specific score. 
The first necessary step, therefore, is obtaining the structures of the isolated 
antigen and antibody. The starting structure may be defined as follows:  
(i) Bound, if it originates from an experimental structure of the complex that 
needs to be docked. 
(ii) Unbound, if it originates from an experimental structure of the molecule 
not bound to the partner that needs to be docked, i.e., either free or bound to a 
different partner. This is the most common scenario for antigens, especially 
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since the number of available protein structures is increasing thanks to several 
structural genomics efforts. Structures of free antibodies, instead, are usually 
not available, nor they would be particularly useful since Abs are known to 
drastically change conformation upon binding49.  
(iii) Modeled, if it has been predicted by homology modeling and/or other 





In order to predict an antibody structure is important remind that the structure 
of the antibodies is governed by very precise rules, especially with respect to 
their antigen binding loops, called complementary determining region (CDR), 
and on the role of individual amino acid residues; in effect these information 
are critical for the antibody design and provides the rational basis for any 
antibody structure prediction method. 
The Antibodies are globular plasma glycoproteins of 150 kDa molecular 
ZHLJKW 7KH PRQRPHU LV D ³<´-shaped molecule that consists of four 
polypeptide chains: two identical heavy chains and two identical light chains 
connected by disulfide bonds. Each chain is formed by structural domains, 
called immunoglobulin domains, that contain about 100 amino acids and have 
DFKDUDFWHULVWLFIROGLQZKLFKWZREHWDVWUDQGFUHDWHD³VDQGZLFK´VKDSHNHSW































Figure 7: Schematic (a) and cartoon (b) representation of a full antibody 




The arms of the Y is called Fab (fragment antigen binding) and can bind two 
antigens, it is composed of one constant and one variable domain from each 
heavy and light chain of the antibody. The variable domain is also referred to 
as the Fv region and contains the CDR loops, three loops on each of the light 
(VL) and heavy (VH) chains are responsible for binding to the antigen; these 
loops are also referred to as H1,H2, H3 and L1, L2, L3.  
The base of the Y is called the Fc (Fragment crystallizable) domain, and is 
composed of two heavy chains and ensures that each antibody generates an 
appropriate immune response for a given antigen by binding to a specific class 
of Fc receptors and other immune molecules such as complement proteins52. 
The canonical structure of the antibodies make them suitable candidates for 
modeling. The most variable part formed by CDR loops can assume just a 
small repertoire of main-chain conformations, FDOOHG³FDQRQLFDOVWUXFWXUHV´53-
55
. 
These conformations are characterized by the length of the loops and by the 
presence of key residues at specific positions in the antibody sequence.  
The canonical structure method is used for the prediction of the antibody 
structure for the most of the web-server, PIGS (Prediction of Immuno 




Antibody Modeling Based on Canonical Structures 
In the canonical method, the sequence of each variable domain VL and VH of 
an unknown structure is aligned with the variable domain sequence of all the 
immunoglobulin of known structure, using standard database searching and 
multiple sequence alignment programs (BLAST, Clustalw)58,59. 
The backbone structure of the framework is modelled using as template 
known structure having higher sequence identity, because higher is the 
residues identity in the core of the two proteins more similar is the 
conformation and also the quality of the model60. 
The prediction of the CDR loop, critical for the antigen binding is also 
predicted using templates having the same loop conformation and sequence 
identity and combining the templates in order to obtain the most accurate 
modeling. Different combinations of templates can be used as showed below. 
(i) Best heavy and light chains. Use the chains with highest sequence identity 
as templates. Since they come from different antibodies, the two chains need 
to be packed together by a least-squares fit of the residues conserved at the 
interface. This may introduce errors in the relative orientation of the two 
chains, with adverse consequences for the accurate modeling of the antigen 
binding site.  
(ii) Same canonical structures. Use a template whose CDR loops have the 
same canonical structures as the target even if a template with higher sequence 
identity exists for one or both chains. If framework and loops are taken from 
different templates, then the loops need to be grafted in, possibly introducing 
errors: the residues adjacent to the loop are superimposed to the framework by 
a weighted least-square fit of the main chain.  
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(iii) Same antibody. Use the same antibody as template for both heavy and 
light chain, even if templates with higher sequence identity exist. This does 
not require optimization of the relative orientation of the two chains and thus 
avoids the errors illustrated earlier.  
(iv) Same antibody and canonical structures. The template is an antibody with 
the same canonical structures as the target and it is used to model both 
framework and the CDR loops. This option does not require optimization of 
framework orientation nor loop grafting and may offer more accurate results 
even if templates with higher sequence identity are available for one of the 
chains. The approach tends to fail, however, if the identity is too low.  
The conformation of five of the six CDR loops can be modelled as described 
but no canonical structure is known for the H3 loop. However, the so-called 
³WRUVR´ UHJLRQ i.e., the H3 residues closer to the framework, can still be 
predicted by similarity to antibodies sharing the same torso conformation60-62. 
7KH³KHDG´ UHJLRQRI+ LQVWHDG IROORZV UXOHVRI VWDQGDUGSURWHLQKDLUSLQV
and can be predicted by similarity to protein loops (not just antibodies) with 
high sequence identity, but the result is usually less accurate than for other 
CDR loops. 
Afterwards the modeling of the side chains happen. At the sites where the 
residues are the same, the conformation of the parent structure is retained. At 
the sites where the residues are different, the side chain conformation is copied 
from antibodies with high sequence similarity or imported from standard 
rotamer libraries63. 
Finally the model is refined by few cycles of energy minimization to improve 
the stereochemistry, especially in those regions where segments of structure 
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coming from different immunoglobulin have been joined and not to refine the 
models significantly.  
Rosetta Antibody Modeling 
Rosetta Antibody64 is a homology modeling program to predict antibody Fv 
structures. It uses a simple energy function to simultaneously optimize the 
CDR loop backbone dihedral angles, the relative orientation of the light and 
heavy chains and the side chain conformations. The program can be 
downloaded and run on local computers or modeling requests can be 
submitted to a web server65. Rosetta Antibody first identifies the antibody 
templates with highest sequence identity for each framework and CDR loops; 
the loop templates are then grafted onto the framework and the full Fv is 
assembled. This crude model is used as input for a second stage: a multi-start, 
Monte-Carlo-plus-minimization algorithm that generates two thousand 
candidate structures. H3 loop conformations are generated by assembling 
small peptide fragments66 and sidechains are finally optimized via rotamer 
packing and energy minimization67. The CDR backbone torsion angles and 
relative orientation of light and heavy framework are also perturbed and 
minimized with a pseudo-energy function that includes van der Waals energy, 
orientation-dependent hydrogen bonding68, implicit Gaussian salvation69, side 
chain rotamer propensities70 and a low-weighted distance-dependent dielectric 
electrostatic energy71. In the end, a scoring function is used to discriminate the 




The Docking Calculation 
Starting from the chosen or generated structures for the antibody and antigen, 
the molecules are then brought together by the preferred algorithm. The 
assumption is that the biological structure having the lowest energy is also the 
correct one because is energetically favored. The scoring function, associated 
to each model coming out of the computational simulation, try to simulate an 
energy by counting for biophysical consideration such as hydrophobic and 
electrostatic interaction, salt bridges, hydrogen bonds, but also statistical and 
empirical consideration such as the degree of conserved residues to the 
interface. 
When searching for the correct binding orientation, the two molecules are 
allowed to move and the score is assessed after each step. A Monte-Carlo 
minimization protocol retain conformation with higher energy in an attempt to 
RYHUFRPHORFDOHQHUJ\PLQLPDWKDWGRQ¶WFRUUHVSRQGWRWKHJOREDOPLQLPXP
The movement is stopped after a predefined number of steps or when the score 
does not improve further. The conformation parameter are changed between 
each step vary in different docking algorithms, which may be divided in three 
general classes as described below:  
(i) Only the relative position of the docking partner is changed;  
(ii) The relative position and the sidechain conformations are changed;  
(iii) The backbone conformation is altered in addition to the above.  
In the simplest case, is called rigid body docking because the conformation of 
the starting structures is not altered at all during the docking process and the 
scoring function only needs to account for the intermolecular interactions72,73. 
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RosettaDock has a first rigid body phase in which sidechains are removed, but 
in a second phase they are re-introduced and their orientation is optimized74,75. 
Since the sidechain conformation is dictated mainly by a limited number of 
allowed torsion angles, the task can be completed with reasonable success and 
limited computational requirements76. Accurately simulating the backbone 
movements that often happen upon formation of biological complexes, 
instead, remains a daunting task for docking, which has a very high failure rate 
when molecules undergo significant conformational changes upon binding. It 
is conceivable that in vivo antibodies adapt to and are selected against existing 
antigen conformations77, thus it might be tempting to believe that antigens 
should not experience drastic changes upon antibody binding. Rigid body 
docking might be best in this case but first of all it is doubtful that proteins are 
not subjected to any conformational motion in solution, not even at the 
sidechain level, and furthermore there are examples in which antibodies 
provoke relatively large allosteric effects on the antigen. 
The issue is slightly different for the antibody, instead: since antibody 
modeling uses bound conformations as templates, the conformational 
rearrangements experienced by the antibody upon binding can be ignored. It 
should be noted, however, that the canonical structures used for antibody 
modeling describe the backbone but not the side-chain conformations, which 
are probably best explored during the docking run. 
In conclusion, if one believes that the antibody model is accurate and that 
antigen binding loops are relatively rigid, then it should not be necessary to 
sample antibody backbone flexibility in the docking run. This assumption 
appears reasonable for the 5 CDR loops following canonical structural rules 
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but it might fail for the H3 loop, the third CDR loop of the heavy chain, which 
may be slightly inaccurate and/or might indeed be flexible in the biological 
context. Conversely, docking methods that vary the CDR loops conformation 
might introduce deviations from the canonical structure and decrease the 
accuracy. Although it is impossible to draw general rules, using rigid body 
approaches for the backbone but sampling different sidechain conformations 
might be a reasonable compromise. It might also prove useful to allow 
backbone movement for the H3 loop (and others when they do not follow 
canonical structures) while allowing only sidechain optimization of the 
remaining antigen binding loops. This behavior can also be approximated by 
generating multiple antibody models, presumably differing mainly in the H3 
conformation, and using all of them as starting structures to be docked without 








Structural characterization of 
the 











Each biomolecule in a living organism needs to adopt a specific three-
dimensional conformation to function properly. Function itself is usually 
achieved by specific interactions between bimolecular units. Structural 
knowledge at atomic level of biomolecules and their interaction is important to 
understand mechanisms leading to biological response and to develop 
strategies to interfere with them when necessary. 
The present study uses a combination of solution NMR mapping, molecular 
biology and computational docking to investigate the structure of the 
chemokine CXCL12 in complex with the chromatin-associated protein 
HMGB1.  
CXCL12 binds to the chemokine receptor CXCR4 and plays an essential and 
unique role in homeostatic regulation of leukocyte traffic. High-mobility 
group box 1 (HMGB1) protein mediates activation of immune responses 
including chemotaxis and cytokine release.  
HMGB1 exerts its chemotactic activity by forming a hetero-complex with 
CXCL12, which acts exclusively through its receptor CXCR4 and not through 
other HMGB1 receptors.  
This study proves that the two proteins indeed interact with each other, 
resulting in an increased CXCL12 cellular activity and maps the regions of the 








Chemokines and their receptors 
Structure 
Chemokines are a group of small proteins ranging from 67 to 127 amino acids 
(8-12 kDa), their sequence is very variable but all share very similar tertiary 
structure. The chemokine family has a characteristic cysteine motif consisting, 
most of the times, of four cysteine residues with two disulfide bonds linking 
the first cysteine with the third, and the second with the fourth, crucial for 
their three-dimensional fold79. NMR and X-ray structures revealed the 
conserved tertiary structure of chemokines, which includes a disordered N-
terminus of 6-10 amino acids that functions as a key signaling domain in all 
chemokines. The N-terminus is followed by a loop ending in a 310 helix, 
connected with three antiparallel ȕ-sheet strands and a C-terminal helix. The 
above mentioned disulfide bonds stabilize the overall topology.  
Many chemokines form dimers or higher order oligomers in solution or upon 
binding to glycosaminoglycans (GAGs). In the so-called CXC chemokines 
UHVLGXHV LQ WKH ILUVW ȕ-strand from one subunit interact with the same strand 
from a second subunit, forming a single, extended six-stranded sheet. The 





Cellular Function and chemokine receptors 
Chemokines play a key role in the migration, homing and retention of immune 
cells. Chemokines bind to specific seven-transmembrane G-protein coupled 
receptors (GPCRs) expressed on the surfaces of their target cells. Binding 
triggers signal transduction events culminating in a multitude of cellular 
responses, such as flux of intracellular calcium (Ca2+) ions, cytoskeletal 
rearrangements or activation of cell adhesion molecules. Cell migration is also 
controlled by expression of different chemokine receptors on the cell surface, 
which recognize specific signals allowing movement of a cell towards an 
inflammation site88. 
Some chemokine receptors bind only specific chemokines, such as the 
CXCR4 (receptor) - CXCL12 (chemokine) pair; other receptors can bind 
several chemokines with different affinity. Peptides derived from the N-
terminal domains of chemokine receptors bind specifically to their respective 
chemokine ligands85,89.  
More than 20 chemokine receptors and 40 chemokines have been identified so 





Table 1: Chemokine receptor ligand, expression and function. 
Functional criteria divide chemokines in  inflammatory or homeostatic classes. 
Inflammatory chemokines are expressed by leukocytes and other cells upon 
activation and have role in both innate and adaptive immunity in response to 
infection and tissue damage. Expression of inducible chemokines is triggered 
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by inflammatory mediators such as tumor necrosis factor, interferon-Ȗ
microbial products or trauma. Their expression is temporary and stops after 
resolution of the situation.  
Homeostatic chemokines are constitutively expressed and coordinate the basal 
level of cell migration needed for proper function of the immune system. They 
navigate leucocytes during haematopoiesis in the bone marrow and thymus, 
during initiation of adaptive immune responses in the spleen and lymph nodes, 
and in immune surveillance of healthy peripheral tissues. Recent findings 
indicate that several chemokines cannot be assigned unambiguously to either 







CXCL12 exists in a monomer-dimer equilibrium that shifts towards dimer in 
presence of various binding partners, including the extracellular domain of its 
receptor CXCR4. The monomeric conformation is favored in acidic 
conditions.  
CXCL12 structure includes a flexible N-terminus connected by an extended 
N-loop and a turn of 310 helix to a three-VWUDQGHGȕ-sheet and a C-WHUPLQDOĮ-
helix91 (Figure 8). The IOH[LELOLW\RIWKHĮ-helix gives CXCL12 a very dynamic 
structure sensitive to solution changes and allowing the switch between 
monomeric and dimeric forms. 
Residues in the flexible N-terminus of CXCL12 are required for CXCR4 
binding, which promotes dimerization of the former, and activation92.  
CXCL12 binds to the extracellular N-terminal domain of CXCR493, which 
must be post-translationally modified by sulfation at three tyrosine residues 





Figure 8: NMR structure of monomeric CXCL12 (PDB ID 2KEE). 
Cellular Function 
CXCL12 is a potent chemo-attractant for lymphocytes, monocytes and 
circulating neutrophils96. CXCL12 signaling via CXCR4 regulates the 
development of T and B lymphocytes and contributes to the survival of mature 
lymphocytes and to the generation of memory T cells97; it also plays a role in 
the homing of hematopoietic progenitors cells to the bone marrow 
microenvironment98. Moreover CXCL12 and CXCR4 are involved in the 
embryonic development of different peripheral tissues including blood 
vessels, muscles and primordial germ cells99-101. Several studies indicate that 
the CXCL12/CXCR4 interaction enhances the inflammatory infiltration of 





H[SUHVVHG LQ KXPDQ EUDLQ E\ QHXURQV DQG PLFURJOLD WKH SULQFLSDO FHOO W\SH
LQIHFWHGE\+,9- LQ WKH&167KHXS-UHJXODWLRQRI&;&5H[SUHVVLRQKDV
EHHQUHSRUWHGLQPDFURSKDJHVPLFURJOLDDQGQHXURQVLQ$,'6SDWLHQWV-
+,9- LQIHFWHG PLFURJOLD RU PDFURSKDJHV UHJXODWH DVWURF\WH &;&/
SURGXFWLRQ WKURXJK ,/-ȕ SURYLGLQJ WKH OLJDQG IRU XS-UHJXODWHG &;&5
7KHDEQRUPDOH[SUHVVLRQRI&;&/DQG&;&5 LQ+,9LVFRQVLVWHQWZLWK
WKH SRVVLELOLW\ WKDW WKHLU LQWHUDFWLRQ PLJKW FRQWULEXWH WR WKH SDWKRJHQHVLV RI
+,9--DVVRFLDWHGHQFHSKDORSDWK\ 
By FRQWUDVW, &;&/ FDQ LQKLELW +,9- LQIHFWLRQ in cells of the immune 
system E\ LQGXFLQJ UHFHSWRU LQWHUQDOL]DWLRQ, WKXV effectively GLPLQLVKLQJ the 
number of &;&5 molecules on WKH FHOO VXUIDFH )XUWKHUPRUH &;&/
VLPLODUO\ WRsmall molecule &;&5DQWDJRQLVWV HJ $0'RU&;&5
VSHFLILF DQWLERGLHV HJ *, FDQ LQKLELW +,9- LQIHFWLRQ LQ YLWUR E\







HMGB1 is a 215 amino acids protein of ~30 kDa composed of three domains: 
two positively charged domains (BoxA and BoxB) connected by a flexible 
linker and a negatively charged carboxyl terminus (the acidic tail). HMGB1 
adopts a closed, dynamic but compact conformation, as shown by nuclear 
magnetic resonance spectroscopy and small angle X-ray scattering109,110. The 
long acidic tail of HMGB1 is flexible and lacks a secondary structure and 
interacts with specific residues in the rest of the protein111. BoxA has WKUHHĮ-
helices folded into an L-shape, whereas BoxB has IRXUĮ-helices folded in L-
shape112 (figure 9).  
 
Figure 9: Solution structure of the tandem HMG box domain from Human 




In the cellular nucleus HMGB1 induces DNA bending by local DNA 
distortion and facilitates the binding of several regulatory protein complexes 
to DNA. Through BoxA and BoxB, HMGB1 enhances transcriptional 
activation and regulates several families of DNA-binding proteins such as the 
p53±p73 transcriptional complexes113,114. When not bound to DNA, the long 
acidic tail of HMGB1 interacts with basic stretches in BoxA and BoxB, 
preventing other interactions111. 
HMGB1 is expressed early during development and it is also widely expressed 
in the adult organism, particularly in immune cells of the thymus and in 
circulating monocytes115. HMGB1 is critical for normal development; indeed 
it was shown that knockout mice suffers from multiple organ failure, small 
size, absence of fat and impairment in bone formation. hmgb1-/- mice die at 




HMGB1 interaction with chemokines 
In addition to the role played in the nucleus, HMGB1 is also found also in cell 
cytoplasm118 and extracellular space119. HMGB1 can be localized to the cell 
periphery and secreted from monocytes, macrophages, dendritic cells and 
fibroblasts. The active secretion of HMGB1 is mediated by acetylation in the 
two major clusters of lysines that act as nuclear localization signals (NLSs). 
Acetylation prevents the interaction of HMGB1 with the nuclear-importer 
protein complex, blocking re-entry into the nucleus120. 
Alternative cytosolic translocation has been observed in neutrophils in which 
HMGB1 is mono-methylated at lysine 42. Methylation supposedly changes 
the HMGB1 conformation and weakens its DNA binding activity, causing it to 
become largely distributed in the cytoplasm by passive diffusion out of the 
nucleus121. 
Finally, HMGB1 can be actively secreted outside cells through stimuli by 
pathogenic LPS and pro-inflammatory cytokines such as IL-1 and TNF. It can 
also be passively secreted from necrotic cells diffusing out into the 
extracellular space122,123. The increase of extracellular HMGB1 concentration 
is mainly related to pathological conditions such as acute and chronic 




Goal of the project:  
HMGB1 interacts with CXCL12 and increases 
its cellular activity? 
It was suggested that HMGB1 can directly and specifically interact with 
CXCL12, increasing its ability to bind to CXCR4 and consequently increasing 
its biological activity. The observation derived mainly by cell migration 
experiments conducted by our collaborators (Uguccioni group, IRB) and thus 
not included in this thesis. Briefly, CXCL12 can induce migration of cells 
expressing the CXCR4 receptor. It was observed that the migration increased 
in the presence of HGMB1 or, more exactly, that in the presence of HMGB1 a 
smaller amount of CXCL12 is required to achieve comparable migration. The 
effect is evident only in the presence of the full HMGB1 protein and not with 
the isolated BoxA or BoxB. Co-immunoprecipitation and other biochemical 
approaches could not provide any conclusive evidence for interaction.  
During my thesis we set forth to 1) demonstrate that HMGB1 can directly 
interact with CXCL12 and enhance its cellular activity and 2) provide a 




We used solution NMR spectroscopy to confirm and characterize the 
interaction between CXCL12 and HMGB1, mainly through chemical shift 
mapping: a highly sensitive tool for characterizing intermolecular interactions, 
mapping binding sites and detecting interacting residues. 
NMR is particularly sensitive to interaction even between low-affinity binding 
partners; simple and rapid 15N-HSQC experiments (see below) can 
unequivocally confirm interaction at the residue level. 
 
Solution NMR spectroscopy 
Solution NMR spectroscopy is ideally suited to the atomic level 
characterization of intermolecular interfaces. NMR mapping can be used to 
rapidly and accurately determine protein/protein interacting interface. 
Basically, the differences in the NMR signal of a protein free or bound to a 
partner will identify the residues involved in the binding and consequently the 
binding surface. 
The NMR signal is exquisitely sensitive to the local chemical environment. 
When an intermolecular complex forms, the chemical environment of 
interface atoms changes as they get close to the atoms of the interacting 
partner and so does their NMR signal. By comparing the NMR spectrum 
before and after complex formation, interface atoms can be individuated due 






Figure 10: schematic representation of an NMR mapping experiment. 
Residues A and B of a 15N-labeled protein (left) generate a single peak in a 
15N-HSQC experiment, schematically shown at the top. Upon binding of a 
second molecule (right), interface residues experience a different chemical 
environment and their NMR signal changes, as shown for residue A. The 
interacting protein is unlabeled and its signals do not appear in 15N-HSQCs. 
Interface residues whose signal is affected by binding can be identified by 
comparing the NMR spectrum of the protein free and in complex. 
 
In a 15N-Heteronuclear Single Quantum Coherence (HSQC) experiment4 the 
backbone NH group of each protein residue (except prolines) generates a 
single NMR signal. The position of these signals is so sensitive to the protein 
conformation that 15N-HSQC spectra are often referred to as protein 
fingerprints. Protein labelling with 15N is required because the naturally 
occurring nitrogen isotope, 14N, is not NMR active. 
The idea behind NMR epitope mapping, schematically illustrated in Figure 3 
and 4, is to (a) record a spectrum of the free, labeled protein, (b) add unlabeled 
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partner protein and record an HSQC of the complex. Because the partner 
protein is not labeled, its residues do not produce an NMR signal and thus do 
not appear in the spectrum. (c) Overlay and compare the spectra of the 
labelled protein free and in complex with the partner protein. If a signal 
changes position, it means that the chemical environment of the residue 
generating it has changed; in other words, the residue is affected by protein 
binding and is likely to belong to the interacting interface. The list of all 
protein residues whose signal changes upon partner protein addition provides 








































Figure 11: Schematic view of NMR epitope mapping experiment. a) HSQC 
spectrum of labelled protein free in solution, b) HSQC spectrum of labelled 




The NMR assignment of the free protein of interest, i.e. knowing which 
residue generate a given NMR peak, is essential for NMR mapping. 
Assignment of the same protein in the complex is not strictly required. If 
NMR changes upon complex formation are minimal then assignment can be 
estimated by simple comparison with the free protein (figure 11). When 
changes are small it is usually trivial to pair each peak in the complex to its 
free counterpart. The larger and more numerous the changes, the less reliable 
this approach becomes. If a protein changes its structure upon complex 
formation, for instance, the NMR signals will change as well and it may be 
impossible to assign it by comparison to the free protein. If complex 
assignment is only available by comparison with the free spectra and 
DPELJXLWLHV DUH SUHVHQW RQH SRVVLELOLW\ LV WR FRQVLGHU WKH µPLQLPXP VKLIW
GLIIHUHQFH¶19. The amount of chemical shift change is defined as the difference 
between a given, assigned, peak in the free spectrum and its closest peak in the 
bound state. This guarantees that the entity of the chemical shift change is 
equal or larger to the one set in the analysis, but it is not overestimated. 
NMR protein assignment requires the use of several aptly designed 
experiments and can require from a few days to years according to protein size 
and sample behavior. Since NMR assignments for both CXCL12 and HMGB1 
are publicly available91,112, we did not need to perform any such experiment 




Can CXCL12 interact with the HMGB1 sub-units, BoxA and 
BoxB? 
As a first step we aimed to ascertain whether CXCL12 can interact with either 
of the two HMGB1 structural domains, BoxA and BoxB. NMR signal 
intensity decreases and increasing molecular weight and spectral analysis 
becomes more and more complicated. Investigating the binding of the 
relatively small HMGB1 subunits allowed us to work in easier to deal with 
NMR conditions. 
CXCL12, BoxA, BoxB and subsequently full HMGB1 were produced in 
Escherichia coli grown in M9 minimal medium either enriched or not with 15N 
and purified according to standard conditions (see methods). 
NMR 15N-HSQC spectra of free 15N-labeled CXCL12 were initially recorded. 
either BoxA or BoxB were subsequently added and 15N-HSQC of the complex 
were recorded. The spectra of free and bound CXCL12 were compared and 
residues whose signal changed upon complex formation were identified. 
These residues are affected by binding and either part of the intermolecular 




Complex between CXCL12 and BoxB 
The NMR signal of 38 out of 68 CXCL12 residues shifted upon addition of an 
















Figure 12: overlay of 15N-HSQC spectra CXCL12 free in solution (blue) and 
in presence of 1:1 ratio of BoxB (red). 
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Residues whose NMR signal changes position upon complex formation were 
identified by visual comparison of free and bound spectra of CXCL12 (figure 
12). A quantitative analysis was also performed: the ³&KHPLFDO 6KLIW
3HUWXUEDWLRQ´ LQGH[ &63 LH WKH amount of chemical shift change upon 
complex formation, was calculated for each residue according to the 
formula ඥሺ ?ܰ  ?  ?Ǥ ?ሻଶ ൅   ?ܪଶ  ZKHUH ǻN DQG ǻH are the chemical shift 
difference between free and bound spectrum in the nitrogen and proton 
dimension (figure 13).  
  
 
Figure 13: Chemical shift perturbation index (y axis) plotted against the 
CXCL12 sequence (residue number shown in the x axis). CSP for the 
CXCL12/BoxB complex are in dark blue and the CXCL12/BoxA complex in 
light blue. 
The majority of the changes in CXCL12 involve residues 13±25, 40±45, and 
the C terminus, whereas the N terminus of CXCL12, in particular the flexible 
first 8 residues known to be required to trigger the CXCR4 receptor cellular 
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activity, are clearly not affected by BoxB binding. Mapping the residues with 
larger CSP on the CXCL12 structure defines a contiguous interacting region 














Figure 14: CXCL12 residues showing significant NMR chemical shift 
changes upon binding of BoxB are highlighted in red on the structure and 




Complex between CXCL12 and BoxA 
Most CXCL12 residues involved in the interaction with BoxB are also 




chemical shift changes were slightly different, probably reflecting interactions 
with residues not conserved between BoxA and BoxB that have a very similar 
structure but only 20% sequence identity. The CSP was generally smaller in 




















Figure 15: overlay of 15N-HSQC spectra CXCL12 free in solution (blue) and 

























Figura 16: CXCL12 residues showing NMR chemical shift changes upon 
binding of BoxB (red) and BoxA (magenta) are highlighted on the CXCL12 
structure (blue). 
 
Although the interacting region of CXCL12 with BoxA and BoxB appears 
remarkably similar, intriguing differences are present. The signal of I51, W57 
and I58 changes in the complex with BoxB but not BoxA (figure 17). These 
77 
 
three residues form a hydrophobic patch at the base of the C-terminal helix, 
which might therefore adopt a slightly different orientation in the two 






Figure 18: Three-dimensional cartoon view of CXCL12. Residues I51, I58 
and W57, showing changes in the NMR signal upon addition of BoxB, but not 
BoxA, are shown as spheres. They form a hydrophobic patch responsible for 
the orientation of the C-terminal helix (red). 
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Mapping the interaction of CXCL12 on BoxB 
In the reverse experiment we mapped the interaction of CXCL12 over BoxB. 
This HMGB1 domain was labelled with 15N and its NMR spectra free or in 
complex with CXCL12 were recorded and analyzed as above.   
44 out of 80 BoxB residues were affected by CXCL12 binding, confirming the 
interaction and pinpointing it to the concave surface formed by the BoxB 
helices. Intriguingly, this is the site where glycyrrhizin binds to HMGB1, 










Figure 19: Cartoon and surface view of BoxB with residues showing changes 
in NMR signal upon addition of CXCL12 colored in red. 
CXCL12 interaction with the full HMGB1 protein 
The addition of full HMGB1 to CXCL12 at a 1:2 ratio causes more extensive 
and profound changes in the 15N-HSQC NMR spectrum of CXCL12 than 
those induced by individual HMG-boxes. 57 of the 68 CXCL12 residues are 
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affected by HMGB1 addition; no signal corresponding to free CXCL12 was 
observed and only one set of peaks is present, i.e. each residue is present in a 
single conformation.  This suggests a 2:1 CXCL12:HMGB1 stoichiometry 
with CXCL12 either assuming the same conformation in the two monomers or 
giving an NMR signal average of the BoxA and BoxB bound conformations. 
 
Figure 20: A) Overlay of the spectra of  CXCL12 free (blue) and in complex 
with full HMGB1 (red) 2:1 ratio. B) Mapping of the residues showing changes 
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in the NMR signal upon complex formation (green) on the cartoon and surface 
view of CXCL12. 
CXCL12 can bind to both HMG-box domains independently but has slightly 
different chemical shifts in the two cases. Since a single set of peaks was 
observed, this suggests that the heterocomplex is dynamic and the CXCL12 
molecules exchange between the free state, BoxA binding, and BoxB binding 
(figure 20). 
Figure 21 offers a comparison of the chemical shift mapping results for the 
binding of CXCL12 to the isolated BoxA and BoxB and to full HMGB1. All 
residues affected by BoxA and BoxB binding are also affected by HMGB1 
binding. Additionally, residues in the N-terminus of CXCL12 and in a loop 
spatially close to the N-terminus are affected by binding to the full protein but 





Figure 21: A) Chemical shift perturbation index plotted against the CXCL12 
sequence. CXCL12 residues showing changes in NMR signal in presence of 
BoxB or BoxA, 1:1 ratio, are in light and dark blue. Residues affected by 
binding to full HMGB1 (2:1 ratio) but not to the individual boxes are shown in 
green. B) Mapping of the above residues on the cartoon and surface view of 
CXCL12. A region around the N-terminus of CXCL12 is only affected by 




Residues 3±12 in the N terminus of CXCL12, which are directly involved in 
CXCR4 recognition and triggering, were affected by the binding of full-length 
HMGB1 but not of either BoxA or BoxB alone. The same is true for the 31±
35 loop, which is spatially close to the N terminus. We know that full HMGB1 
can increase the cellular activity of CXCL12 whereas the individual boxes 
cannot. Intriguingly, the CXCL12 residues known to interact with the cellular 
CXCR4 receptor (and thus triggering activity) are affected by binding to the 
full protein but not to the individual boxes. This suggests interesting biological 




Surface Plasmon Resonance 
Cross competition experiments to further probe the 
HMGB1/CXCL12 interface 
We used Surface Plasmon Resonance (SPR) to further probe the interaction of 
CXCL12 with HMGB1. Detailed explanation of the SPR technology is 
available in the methods but, briefly, the idea is to immobilize one protein on a 
sensor surface and record a signal if and when a second molecule is added and 
interacts with the immobilized one. Analysis of the signal allows 
determination of association and dissociation rates as well as overall binding 
affinity. 
Both CXCL12 and HMGB1 were immobilized on the sensor surface in a 
plethora of different conditions. Unfortunately, unspecific binding was always 
present and did not allow the reliable determination of binding properties. 
8QVSHFLILF ELQGLQJ KDSSHQV LI WKH SURWHLQ IORZHG LQ VROXWLRQ ³VWLFNV´
unspecifically to the sensor surface instead of interacting specifically with the 
immobilized protein. As a consequence, the recorded SPR signals do not 
reflect a real interaction but rather the deposition of protein on the sensor 
surface. It is perhaps worth reminding the unspecific signal can be reliably 
identified if, for instance, an SPR signal is recorded in a control channel 


























Figure 22: SPR experimental scheme (left) and sensorgrams (right) with 
immobilized HMGB1, either in reduced or oxidized form, and CXCL12 in 
solution (Phosphate buffer pH 6 in this experiment). Although a dose response 
is clearly present, unspecific binding of CXCL12 to the sensor surface 
























Figure 23: HMGB1 oxidized and reduced immobilized on the chip surface 



























Figure 24: HMGB1 oxidized and reduced immobilized on the chip surface 
and CXCL12 flowed in solution at pH 4.5 (monomeric). 
 
Since we could not directly probe and characterize the interaction with SPR, 
we set up a cross competition experiments to try to circumvent the unspecific 
binding problem. Glycyrrhizin, a component of liquorice, was shown to inhibit 
the chemo-attractant and mitogenic activity of HMGB1126.  It was also shown 
to bind to the concave part of both BoxA and BoxB, in a region of HMGB1 
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that is also affected by CXCL12 binding. We hypothesized that CXCL12 and 
glycyrrhizin share a binding site on HMGB1 and that, therefore, can cross-
compete with each other. We thus immobilized HMGB1 on a SPR sensor and 
then added glycyrrhizin at concentrations of 0, 500, or 5000 nM; 500 nM 
CXCL12 was finally added in a third and final step.  
An SPR signal was detected in all cases, which is not surprising since there is 
unspecific binding (and thus signal) of the chemokine to the sensor surface. 
However, the signal intensity decreases at increasing glycyrrhizin 
concentration (figure 18). Since the SPR signal intensity is proportional to the 
DPRXQWRISURWHLQ³GHSRVLWHG´RQWKHVHQVRUVXUIDFHHLther through interaction 
with the immobilized partner or by unspecific binding, a signal decrease 
indicates that the presence of glycyrrhizin inhibits CXCL12 binding. The SPR 
signal does not drop to zero because unspecific binding of CXCL12 to the 
sensor surface is not abolished by glycyrrhizin, whereas less and less CXCL12 
can bind to HMGB1 in the presence of increasing concentration of 
glycyrrhizin, reflected by the decreased SPR signal. The experiment was 
obviously repeated at least 3 times in each condition tested and several 
reference channels were used, for instance flowing CXCL12 or glycyrrhizin 





Figure 25: SPR sensorgrams of the interaction between HMGB1 and 
CXCL12 in the presence of increasing concentration of glycyrrhizin. HMGB1 
was immobilized on the SPR sensor surface; glycyrrhizin was added at 0 
(blue), 500 (green) or 5000nM (red). Finally, 500nM CXCL12 was added to 
each channel, recording the SPR response shown in the image. Glycyrrhizin 
inhibits CXCL12 binding, reflected by a decrease in SPR signal. Complete 
loss of signal is not achieved because unspecific binding of CXCL12 to the 




Computational Docking  
We used computational docking, the process of predicting the structure of a 
complex starting from the separate structure of its individual components47, to 
obtain a three-dimensional atomic model of the CXCL12/HMGB1 complex. 
Experimental structures of both proteins are publicly available (PDB ID. 
2KEE and 2YRQ).  
Protein-Protein docking starts with the two molecules separated by typically 
25Å and then brought together by the preferred algorithm. Translational and 
URWDWLRQDOPRYHPHQWVJHQHUDWH³SRVHV´ZKRVHHQHUJHWLFVFRUHLVHYDOXDWHGE\
apt scoring functions. The process stops after a pre-determined number of 
³PRYHV´ RU ZKHQ WKH VFRULQJ IXQFWLRQ GRHV QRW LPSURYH DIWHU VXEVHTXHQW
moves, indicating that the system has reached an energy minimum.  
Each docking run generates thousands of models (decoys) of the complex and 
evaluates them in term of an empirically determined scoring function that 
attempts to represent energy states (pseudo-energy). Simply put, each 
hydrophobic and electrostatic interaction, salt bridge, hydrogen bond etc. 
contribute to a global score; statistical and empirical considerations such as the 
degree of conserved residues in the interface can also be taken into account. 
The assumption is that the structure having the lowest energy is also the 
biological one, although this is not always true. 
When searching for the correct binding orientation, the two molecules are 
allowed to move and the score is assessed after each step. A Monte-Carlo 
minimization protocol retains some conformation with higher energy in an 
DWWHPSWWRRYHUFRPHORFDOHQHUJ\PLQLPDWKDWGRQ¶WFRrrespond to the global 
minimum. The movement is stopped after a predefined number of steps or 
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when the score does not improve further. The conformation parameters 
changes in different docking stages and algorithms, which may be divided in 
three general classes: (i) only the relative position of the docking partner is 
changed; (ii) the relative position and the sidechain conformations are 
changed; (iii) the backbone conformation is altered in addition to the above.  
The simplest case is called rigid body docking because the conformation of 
the starting structures is not altered at all during the docking process and the 
scoring function only needs to account for the intermolecular interactions72,73. 
Rosetta-Dock, the algorithm used in this thesis, has a first rigid body phase in 
which sidechains are removed, but in a second phase they are re-introduced 
and their orientation is optimized74,127. 
The simulation of backbone movements that often happen upon formation of 
biological complexes, instead, remains a daunting task for docking, which has 
a very high failure rate when molecules undergo significant conformational 
changes upon binding. 
A plot of the score of each decoy (scoring plot) is often used to obtain a visual 
representation of a docking run (figure 26). The presence of a  ³VFRULQJ
funnel´LQGLFDWHVWKDWWhe process is finding several similar structures with low 
energy, which is usually considered an indication of accuracy (care must 






Figure 26: Scoring plot. Each dot corresponds to a docking model obtained 
during the simulation. Lower values for the scoring function (pseudo-energy, 
y-axis) indicate solutions considered more accurate by the docking algorithm. 
The x-axis show structural difference (RMSD) to a reference structure; similar 
RMSD values tend to indicate similar structures.  
 
Although docking algorithms are constantly improving, scoring function often 
fail to discriminate accurate from inaccurate solutions. Experimental data from 
NMR studies, like the mapping we conducted on the HMGB1/CXCL12 
complex, can provide a huge help to discriminate accurate solutions128.  
Indeed NMR chemical shift perturbation (CSP) analysis identifies the region 
of the proteins affected by binding during complex formation and thus likely 

























Figure 28: The best model obtained for the complex between CXCL12 and 
BoxA. Top:  surface view of CXCL12 with the binding region, according to 
NMR chemical shift mapping experiments, shown in blue. Bottom: docking 
model of the complex between BoxA (orange) and CXCL12.  There is no 
good agreement between computational and experimental data. 
 
The docking simulation of CXCL12 in complex with BoxB was performed 
with different approaches because BoxB (in the construct used for the NMR 
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experiments) contains an unstructured linker that connects it to BoxA. First of 
all the docking simulation was run between CXCL12 and ³full´%R[%EXWWKH
unstructured linker interfered with the position of CXCL12. This situation is 
probably unrealistic, since the linker would be free to move out of the way in 
reality but is not allowed to do so during the simulation. For this reason, a 
second set of docking simulations was performed removing the tail from the 
docked construct (figure 29).  
 
 
Figure 29: The best model obtained during the simulation between CXCL12 
and BoxB. Top: surface view of CXCL12 with the binding region obtained 
with NMR chemical shift mapping experiments in blue. Bottom: overlays of 
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two docking models with BoxB shown in orange. In both models there is good 
agreement between docking and experimental data.  
 
Unfortunately, the binding region experimentally defined on the CXCL12 
structure is vast and covers most of CXCL12; as a consequence it was not 
possible to define a unique solution; on the contrary, several docking models 
equally satisfied the experimental data and are, therefore, considered equally 










Figure 30: Top: Docking between CXCL12 (grey) and BoxA (orange), with 
the NMR defined binding region in cyan. Several docking models are 
overlaid. Bottom: as above for the CXCL12/BoxB complex. 
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Computational docking was unable to define a reliable atomic model for the 
complex between HMGB1 and CXCL12. One possibility is that HMGB1 
and/or CXCL12 might undergo conformational changes upon binding, 
something that computational docking cannot effectively simulate. At the 
same time, the docking models with best computational score and the 
agreement with the NMR mapping data suggest that both BoxA and BoxB 





Discussion and conclusion 
Cellular experiments indicate that the cellular activity of CXCL12 is enhanced 
by the presence of HMGB1 protein. A direct interaction between the two 
entities could, however, not be established. 
Our NMR studies prove that both BoxB and BoxA use the kink in their 
structure, corresponding to the DNA binding site, to bind CXCL12. The 
experiments define the CXCL12 region responsible for HMGB1 binding, 
which involves the globular domain and is identical in the complexes with the 
two Boxes. In our hypothesis two molecules of CXCL12 interact with one 
molecule of HMGB1 by direct binding to the individual HMGB1 subunits. 
Binding involves the globular part of CXCL12, composed of one alpha helix 
and 3 beta strands, and the concave region of the HMGB1 subunits, which is 
also the glycyrrhizin binding site.  
CXCL12 is known to dimerize in certain conditions and an experimental 
structure of a CXCL12 dimer is available, although this is somehow artificial 
since the two subunits were covalently cross-linked129. Our data excludes that 
such dimer is formed in the presence of full HMGB1. NMR mapping shows 
that the dimer interface residues are not affected by HMGB1 binding. This 
























Figure 31: Dimeric conformation of CXCL12 (PDB ID 2K01), the two 
monomers are highlight in dark and light blue on the top while on the bottom 
orange and red indicate the residues affected by the formation of the 
CXCL12/HMGB1 complex. 
 
What we propose, instead, is a model with the N-terminal tail of the two 
CXCL12 monomers arranged in a parallel fashion, as in figure 26. In such 
configuration the CXCL12 N-terminus does not contact BoxA or BoxB, in 
agreement with NMR mapping showing that they are not affected by binding. 
Upon binding to full HMGB1, instead, the two N-terminus regions might 
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interact with each other, in agreement with the NMR mapping data showing 
that they are indeed affected by full HMGB1 binding (figure 32). 
 
Figure 32: Hypothesis of interaction between CXCL12 and HMGB1. Two 
molecules of CXCL12 bind one molecule of HMGB1, the globular head of 
CXCL12 binds to the kinks of the HMGB1 sub-units. 
 
It is important to note that the presence of either Box is sufficient for binding 
to CXCL12 but not to enhance its cellular activity which is, instead, increased 
in the presence of full HMGB1. NMR shows that the flexible N-terminus 
residues, as well as a spatially close loop, are affected only by binding to full 
HMGB1. Residues 3-12 of CXCL12 residues are required for CXCL12 to 
interact with its cellular receptor, CXCR4, and to trigger its cellular activities. 
The modality of interaction of CXCL12 with its receptor is known and it is 
well explained by the ³Fish and Rod´ model130 ,QLWLDOO\ UHVLGXHV LQ WKH ȕ-
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VKHHWĮ-helix of CXCL12 interact with the extracellular loops of the CXCR4 
receptor. This facilitates the anchoring of CXCL12 to CXCR4 with the 
CXCL12 N-terminus remaining highly mobile (as shown by NMR dynamics 
studies130). This mobility allows the N-termLQDO UHVLGXHV WR ³SUREH´ WKH
binding cavities buried within the transmembrane helices of CXCR4. In a 
second step of interaction the CXCL12 N-terminus is inserted in the 
transmembrane helices, presumably immobilized, triggering conformational 
changes in CXCR4 that induce G-protein signaling. Blocking the flexible N-
terminus in a single, probably rigid, conformation requires a certain entropic 
cost. In our proposed model there are three partners: CXCL12, HMGB1 and 
CXCR4. Binding to full HMGB1 puts the CXCL12 N-terminus in a 
conformation ready to interact with CXCR4. The energy spent to lock into 
such orientation is paid by HMGB1 binding. As a consequence, binding of the 
HMGB1/CXCL12 complex to CXCR4 would be energetically more 
convenient than binding of CXCL12 alone, explaining the increased cellular 
activity of this chemokine in the presence of HMGB1. There are strong 
suggestions that CXCR4 dimerizes on the cell membrane; the presence of two 
CXCL12 molecules bound to HMGB1 could also favor interaction with the 
receptor dimer, either by putting CXCL12 in the right conformation for 
interaction (as above), or simply by rendering the binding of the second unit 
more favorable after the first one has locked onto CXCR4, effectively 









Figure 33: CXCL12 free in solution (A) with the highly mobile N-terminus 
shown as lines in multiple conformations. In our hypothesis HMGB1 binds 
two molecules of CXCL12 and locks the N-terminus in a single conformation 








Rational engineering of human 
antibodies through 
experimentally validated 




Dengue virus (DENV) is a mosquito-borne flavivirus that in recent decades 
has become a major international public health concern146. 
The virus is found in tropical and sub-tropical regions, predominantly in 
urban areas, and an estimated 3.5 billion people, or half WKH ZRUOG¶V
population, are at risk of infection, with the number constantly 
increasing146,149. 
The long term aim of my work is to understand why some antibodies are 
able to neutralize only some Dengue serotypes but not others and why most 
antibodies facilitate subsequent infection by other serotypes (Antibody 
Dependent Enhancement) , leading to the insurgence of Dengue 
Hemorrhagic Fever (DHF)149. 
In order to reach this goal, the main objective of this project is the 
structural and biophysical characterization of new neutralizing and/or 
enhancing antibodies from Dengue virus recovered subjects. 
In particular, we want to compare the binding of the same antibody to the 
four Dengue serotypes and the binding of different antibodies to the same 
serotype, therefore it is necessary to determine several different antibodies-
DIII structures. 
Traditional experimental techniques like X-ray crystallography or NMR 
spectroscopy can give us very precise and accurate results but are long and 
expensive methods. If we want to characterize a large number of Ab-Ag 
complexes, instead, we cannot rely on these methods but need a faster 
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approach. Computational docking might be such an approach and even if 
its results are not going to be as accurate and precise as an x-ray structure, 
sacrificing precision for speed might be worthwhile if looking for general 
trends in a large panel of structures. 
In a typical docking simulation the structures of the individual partners are 
brought together by the chosen algorithm. While we know the 
experimental structure of DIII, we need to model the structure of the 
antibodies of interest. The presence of a conserved framework region, and 
the fact that most CDR loops have access to a limit number of canonical 
structural classes make antibodies particularly suitable for homology 
modeling prediction. Uncertainties arise in the relatively rare cases when a 
loop is particularly long and/or does not follow canonical structures. The 
H3 loop does not appear to adopt canonical structures, instead, and 
predicting its conformation requires more sophisticated and less accurate 
approaches. 
In order to overcome this problem, in our approach we obtain 11 different 
models of the antibodies and we dock each of them independently with 
Dengue, in order to explore the effect of different loop conformations and 







Dengue virus (DENV), a mosquito-borne flavivirus like West Nile Virus and 
Yellow fever, is the causative agent of dengue fever, one of the most 
significant emerging disease challenges to global public health131,132. 
Dengue virus is responsible for ׽100 million annual human cases, including 
500,000 hospitalizations and 20,000 deaths with an economic burden rivaling 
that of malaria. Although DENV has been mainly restricted to the tropical 
region, both its epidemic activity and its geographic expansion are increasing 
as travel, urbanization, and climate changes create favorable conditions for 
vector and virus dissemination, with an estimated 2.5 billion people at risk of 
infection133-135. 
 
At present, neither a vaccine nor anti-viral drugs are available, prompting 
research initiatives aimed at understanding the molecular and cellular 
virology, genomics and evolution of this important virus. The effort to find a 
vaccine has been hampered by the presence of four different dengue serotypes 
(DENV1±4) and by a poorly understood process, antibody-dependent 
enhancement (ADE). Antibodies raised against a previous Dengue infection 
facilitate subsequent infection by a different serotype and lead to 
Dengue Hemorrhagic Fever (DHF), a more severe form of the disease with 
fatality rates that can surpass 20% but fall below 1% with appropriate 
supportive care136-138. This feature complicates the task of finding a vaccine, 
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since a vaccine that would not protect equally against all four serotypes would 
actually contribute to the emergence of Dengue Hemorrhagic Fever139. 
In order to understand a good approach is to Characterizing and comparing the 
binding of several antibodies to the viral surface protein of the four different 
Dengue serotypes is expected to improve our understanding of the molecular 
basis of neutralization and ADE. In particular, this strategy allows us to 
answer two main questions regarding the immunological properties of Dengue 
virus: 
 
 Do all the antibodies that confer protection from disease bind to the same 
region of Dengue? If this is the case than we could identify such binding 
region and ideally exploit this knowledge to design a vaccine mimicking it. 
 
Are there common properties amongst the antibodies capable of neutralizing a 
given serotype? If so we may introduce such properties in new antibodies 
lacking them, designing new molecules or optimizing the existing ones for 
passive immunization. The Dengue virus particle is a sphere with a diameter 
of approximately 500 Å and is composed of a single, positive-strand RNA 
genome packaged by a virus capsid protein in a host-derived lipid 
bilayers140,141. 
 
The viral surface is formed by 180 copies of an envelope glycoprotein called E 
protein. E protein forms a dimer and is the dominant target of the response 
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consisting of antibodies against Dengue. Each monomer is subdivided in three 
domains: DI, DII and DIII. The central structural domain (domain I) contains 
the N-terminus and is flanked on one side by an elongated dimerization 
domain (domain II) which contains the fusion peptide at its distal end. On the 
other side of domain I is domain III, an immunoglobulin (Ig)-like domain 
thought to contain the receptor-binding sites141.(Fig. 34) The latter is the 
favorite target of neutralizing antibodies against Dengue and is also the most 
variable region amongst different Dengue serotypes, making it an attractive 
target for our structural immunology studies142-146. 
Since the cellular effect of an antibody (Ab) starts, in ultimate analysis, with 
specific atomic interactions between the Ab itself and the pathogen, a 
structural comparison of several different Ab/DIII complexes could provide 
insightful clues on the features needed for effective DENV neutralization and 
enhancement147. Ideally we want to compare the binding of the same Ab to 
DIII of different serotypes and the binding of different Abs to the same 
serotype. If we want to observe many structures, however, we need an 
approach faster than traditional experimental techniques such as X-ray 
crystallography or NMR spectroscopy. Computational structural biology has 



















Fig.34 Three-dimensional structure of Dengue virus. (a) the entire surface 
of the virion formed by 180 copies of envelope protein (E protein) that 
forms dimers, shown in panel (b). (c) The E-protein monomer is formed by 






The epitope of antibody DV32.6 on Dengue1 DIII 
 
We characterized the binding of DV32.6, the same antibody described in the 
JMB paper35, to DENV1 and here compare it to DENV4.  
Thirty-two residues of the E protein domain III of Dengue serotype 1 are 
affected by the binding of DV32.6. The epitope is almost identical to that of 
DENV4-DIII, at least at the residue level. Aligning the structure of 
DENV1/DIII with the one of DENV4/DIII and mapping the residues that 
experience a shift in their NMR signal on the surface of DENV1/DIII, as we 
done for DENV4/DIII, we can observe a slight difference position of the 























Fig. 35 Residues whose NMR signal changes upon interaction with DV32.6 
are mapped on the surface of DENV1/DIII (a) and DENV4/DIII (b). DIIIs 
are colored in different shades. Residues showing significant chemical shift 







Binding of DV32.6 to DENV1 E protein domain III 
 
Using RosettaDock software we perform docking simulations using the 
experimentally obtained structure of DENV1/DIII and each of the eleven 
structures of DV32.6 antibody obtained with RosettaAntibody and PIGS 
servers. As for the case of DENV4/DIII, not all of them give a docking result 
that is in accordance with NMR experimental data. The models of the complex 
obtained using Models 4 and 8 show no violation according to the NMR and 











Fig. 36 Docking multiple models of the Ab. (a) Superposition of all DV32.6 
models showing no violation; DENV1/DIII and the epitope are colored as in 
the previous figure; the Abs are shown as cartoon. The heavy and light chains 
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are in dark and light green, respectively. (b) Top line: the NMR epitope is 
mapped on the sequence of DIII. Residues with significant chemical shift 
changes are in red, while residues with small changes are in purple. Residues 
for which no NMR mapping information is available, either because of 
overlap or because of lack of assignment, are in gray. Bottom lines: interface 
residues are highlighted for each model. Residues at the interface according to 
both the NMR and SASA criteria (see attached paper) are in green. If they are 
at the interface according to the NMR but not the SASA criterion, they are 
shown in dark green. If they are at the interface according to the SASA but not 
NMR criterion, they are in cyan. Models 4 and 8 have no violations. 
 
In contrast to DENV4, where DV32.6 utilizes the light chain CDR loops plus 
the H3, the antibody contacts DENV1 using also the H1 and H2 loops (D33 in 
H1 loop has a ionic interaction with K400 while S52, S55 and Y57 in H2 loop 



















Fig. 37 Footprints of DENV1/DIII and DENV4/DIII on DV32.6. The 
surface of DV32.6 is shown, with heavy and light chains colored in dark and 
light green, respectively. Residues that make contacts with the DENV1/DIII 
are colored light-violet (a), while the ones that interact with DENV4/DIII are 
colored in purple (b). 
 
The center of the binding is characterized by interactions between D50 and 
D51 of the light chain of DV32.6 with three lysines in the center of the 
epitope. In particular, the side chain oxigen of D50 makes a hydrogen bond 
with the NH3 group of K310 while the two oxigens of D51 bridge the NH3 
groups of two lysines on the antigen, K307 and K325. Furthermore, the side 
chain oxygen of D102 on the Ab makes an hydrogen bond with the side chain 





















Fig. 38 Atomic details of DV32.6-DENV1/DIII interaction. (a) Hydrogen 
bond interactions at the core of the Ab/Ag interface between Asp50 and 
Asp51 of DV32.6 L2 loop and Lys307, Lys310 and Lys325 of DENV1/DIII. 
(b) Hydrogen bonds between Ser52 and Ser55 of DV32.6 H2 loop and Ser396 
and Ser397 of DIII. (c) Ionic interaction between Asp102 in H3 loop and 
Lys310 of DIII. Nitrogen and oxygen atoms are shown in blue and red, 
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respectively, whereas hydrogens are in white. Possible hydrogen bonds are 
indicated by broken lines. DIII is shown in light blue, while the Ab is in green. 
Model 8 is shown. 
To sum up, comparing the structure of the complexes between DV32.6 and 
DENV1/DIII or DENV4/DIII, our results show that the L2 loop of the 
antibody, and in particular the two aspartates in position 50 and 51, play an 
important role in both cases. DV32.6 interacts more extensively with 
DENV1/DIII rather than DENV4/DIII, having contacts with 5 of its 6 CDR 
loops. Furthermore, the binding orientation of DV32.6 is different in the two 










Fig. 39 Different orientation of DV32.6 in complex with DENV1/DIII (a) and 
DENV4/DIII (b). The DIIIs of the two serotypes are aligned. Only the models 
that are in agreement with the experimental data are shown. The yellow and 
116 
 
orange lines is the schematic representation of the orientation that the antibody 
assumes when it interact with DENV1/DIII and with DENV4/DIII. 
 
How DV32.6 interact with DenV serotypes 
The step over in the understanding of the interactions between DV32.6 and 
DenV serotypes was elucidate the structure of DV32.6 in complex with all the 
remaining DenV serotypes and exploit the differences to rationally design 
mutated antibodies with i) selectively altered binding specificity and ii) 
improved ability to neutralize the virus. First of all has been used NMR 
epitope mapping to define the binding site of DV32.6 on DIII of all four DenV 
serotypes. Then use this information to filter computational predictions of the 
antibody/antigen complexes. Analysis of the resulting three dimensional 
structures proved sufficiently accurate for the rational design of antibody 
mutants with selectively altered binding specificity or improved neutralization 
properties. 
DV32.6 is part of a panel of human monoclonal antibodies isolated from a 
donor recovered from infection by DenV2145. It binds to DIII of all four DenV 
serotypes with KD 145±9 nM for 
DenV1; 7±0.2 nM for DenV2; 73±16 nM for DenV3; 34±7nM for DenV4 






Fig. 40 SPR sensorgrams showing association and dissociation of DV32.6 to 
DIII of each Dengue serotype. The antibody was immobilized on the sensor 
surface, followed by injection of DIII at the concentrations indicated in the 
figure. The line fitted to the experimental data and used to calculate the 
binding affinities is drawn in gray. KD values are 145±9 nM for DenV1; 
7±0.2 nM for DenV2; 73±16 nM for DenV3; 34±7 for DenV4. Despite 
binding more weakly to DenV1 and DenV3 than DenV4, the antibody 
neutralizes those serotypes better than DenV4. 
 
The ability of DV32.6 to neutralize the virus was assessed by flow cytometry 
assays measuring the number of cells infected by DenV vaccine strains  in the 
presence of different amounts of antibody. There is no direct correlation 
between DIII binding affinity and neutralization: the antibody is more efficient 
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at neutralizing DenV2, DenV1 and DenV3 despite binding more strongly to 
DIII of DenV4. 
 
Association and dissociation rates show no obvious correlation to the 
neutralizing activity, either. The approximate concentration of antibody 
required to neutralize 50% of the viral activity is 2mg/ ml for DenV2, 3mg/ml 
for DenV3, 4mg/ml for DenV1 and 74mg/ml for DenV4. Binding assays on 
isolated DIII allow us to compare the binding affinity of the antibody for its 
epitope but the natural target for the antibody is the full virus, where the 
surface of DIII is partially covered by neighbouring protein domains. In 
contrast to DIII binding, ELISA performed at 37°C on the full virus show that 
binding to DenV4 is not stronger than to other serotypes.  
Solution NMR spectroscopy was used to characterize, at the residue level, the 
epitope of DV32.6 on DIII from each DenV serotype. In a so-called 15N-
HSQC experiment, the position of these signals is sensitive to the local 
chemical environment, so much so that 15N-HSQCs are considered protein 
fingerprints. We exploit this property to determine the epitope: when DV32.6 
binds to DIII, interface residues experience a different chemical environment 
and their NMR signal changes as a consequence. By comparing the NMR 
spectrum of DIII free or in complex with the antibody we can identify which 
signals change. Knowing the assignments, we can therefore determine the 




Fig. 41 15N HSQC spectra of DIII of the four Dengue serotypes free (blue) 
and in complex with antibody DV32.6 (red). Residue V324 is affected by 
complex formation and shows chemical shift changes in DenV1, DenV3 and 
DenV4 but not DenV2. Residue K310 shows chemical shift changes upon 
complex formation in DenV4 and DenV1 (smaller changes). The peak 
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corresponding to the bound state disappears in DenV2 and DenV3, revealing 
that the residue is affected by antibody binding. 
We assigned DIII of DenV3 according to standard techniques. We utilize a 
purely qualitative approach: if a signal changes position or disappears, then we 
know that the residue generating such signal is affected by antibody binding.  
The NMR signal of approximately 20% of the surface residues of DIII is 
perturbed upon binding of DV32.6. No unassigned peak shows chemical shift 
changes upon complex formation with the exception of one signal that 
presumably belongs to Q316, in the middle of the epitope. The epitope centers 
around residues 306±325 and the antibody footprint shows only slight 
variation amongst serotypes (Figure 42a and 42b). 
 
Fig. 42 NMR epitope mapping results (a, b): residues whose NMR signal is 
affected by antibody binding are indicated in red on the sequence (a) and on 
the surface representation (b) of DIII of each DenV serotype. Residues for 
121 
 
which no NMR information is available are coloured gray in the sequence. 
The discontinuous epitope shows slight variations amongst serotypes both in 
sequence and structure, including some conserved residues and others that are 
not. The former explain why DV32.6 can bind to all four serotypes, the latter 
are likely responsible for the different binding and neutralization properties. 
Computational docking results (c). Surface representation of the antigen 
binding site of DV32.6. Antibody residues predicted to interact with DenV are 
shown in blue; light and heavy chains are in light and dark gray, respectively. 
Both antibody chains contribute to the binding interface in DenV1 and DenV3 
whereas only the light chain and the H3 loop bind to DenV2 and DenV4. 
Some of the residues mutated to alter the antibody properties in a predictable 
way (see text) are indicated by red circles and labelled on DenV1. 
 
It includes residues conserved in all serotypes, explaining why DV32.6 binds 
all four of them, and residues that are not conserved, which are probably 
responsible for the different binding and neutralization properties. To further 
characterize the binding interface we thus predicted the three dimensional 
structure of the complex between DV32.6 and DIII by computational docking, 
guided and validated by the NMR epitope mapping data. 
We predicted the structure of antibody DV32.6 by homology modeling 
according to the canonical structure method. Then thus generated multiple 
models of DV32.635, differing mainly in the conformation of the H3 and L3 
loop and in the relative position of the six antigen binding loops. In particular, 
the H3 loop extends outwards in some of our models but presents a rather flat 
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interacting surface in others. The purpose is two-fold: on one hand by using 
multiple models we increase the chances that at least one of them is accurate; 
on the other hand the ensemble of conformations may simulate the flexibility 
available to long protein loops such as the H3 of DV32.6. We then docked 
each antibody model independently to DIII with the program RosettaDock148 
and validated the results. 
According to our NMR validated docking predictions, DV32.6 primarily 
recognizes DIII residues located on adjacent beta strands, covering between 25 
DQGUHVLGXHVZLWKDEXULHGVXUIDFHDUHDEHWZHHQ$Û2 (DenV2) and 768 
$Û2 (DenV1). These values are in line with those obtained from x-ray 
structures of other antibodies against DIII. The predicted interface of antibody 
DV32.6 is dominated by electrostatic interactions and features several 
intermolecular hydrogen bonds and salt bridges. All DIII residues predicted to 
be at the interface by the selected docking solutions are also affected by 
complex formation in the NMR epitope mapping experiment. K310, 
conserved in all serotypes, is at the center of the interface and involved in 
multiple intermolecular contacts. The epitope has several non-conserved 
residues, which are probably responsible for the different binding and 
neutralization properties of DV32.6. Indeed, residues 307, 309, 323, 325 and 
327 differ among serotypes and appear to be involved in antibody binding. 
Residue 309, for instance, is Glu, Val, Lys or Asp in DenV1 to DenV4, 
respectively, and it may not be surprising that it has a different effect on the 
antibody partner. Perhaps surprisingly, some conserved DIII residues appear 
to have different antibody partners in different serotypes:  
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Analyzing the predicted antibody interface (Figure 42c) shows differences that 
could be exploited to selectively alter the binding properties: the light chain 
(L1, L2, L3) and H3 antigen binding loops interact with every serotype; the 
H2 loop interacts only with DenV1 and DenV3 and the H1 loop has no contact 
with any serotype. Although the total interface area is similar, the light and 
heavy chains equally contribute to it in DenV1 and DenV3, whereas 80% of 
the interface is formed by the light chain in DenV2 and DenV4 
 
Rational Antibody Engineering to Selectivity Alter 
its Binding Properties 
By analyzing the three-dimensional models of the antibody/DIII complexes 
we designed several antibody mutants with the intent of further verifying our 
computational predictions, altering the binding properties of the antibody and 
ultimately improving its ability to neutralize the virus. As a first test we aimed 
to modify the antibody without affecting its binding to DIII, proving that we 
can identify and avoid critical residues. Antibody sequence analysis can easily 
predict which residues belong to antigen binding loops and may, therefore, 
interact with the antigen. Our models go a step further and can identify which 
of these residues are not directly involved in intermolecular contacts and can 
thus be mutated without adverse consequences. We thus selected and mutated 
a subset of such residues in each of the three heavy chain antigen binding 
loops. As predicted, all the following mutations in the antigen binding loops 
124 
 
GLGQ¶WDOWHUWKHDQWLERG\ELQGLQJSURSHUWLHV+-S104A (Figure 3); H-T31A; H-
S54Q; H-S103V; H-T106A.  
To further validate our models we then aimed to abolish antibody binding to 
all serotypes. Residues L-D50 and L-D51 are predicted to be at the center of 
the antibody/DenV interface, forming an intermolecular network of hydrogen 
bonds and salt bridges in all serotypes. If our models are correct, disrupting 
this network should have a profound effect on the interface. Indeed, the double 
mutant L-D50A/D51A completely abolishes antibody binding (Figure 3). The 
same result is obtained when mutating the nearby H-S105D, since the negative 
charge introduced interferes with the negatively charged sidechain of L-D50. 
Having shown that our approach can identify critical interface residues, we 
tackled the much more difficult task of improving the antibody properties. 
Generally speaking, increasing antibody selectivity is a useful exercise to 
eliminate cross-reactivity with undesired antigens or to design bio-recognition 
elements for specific antigen subtypes. As a proof of concept, we altered the 
interaction between DV32.6 and DenV, obtaining an antibody mutant specific 
for DenV2 and another that binds only DenV2 and DenV4. According to our 
models, residues H-D102/S103, belonging to the H3 antigen binding loop, 
point away from the DenV2 antigen. Therefore, mutating them should have no 
effect on this serotype. They are, instead, in close proximity of DenV4 and 
DenV3. Finally, H-D102 is predicted to form an intermolecular salt bridge in 
DenV1. In agreement with this prediction, the HD102A/S103A mutant binds 
DenV2 like the wild-type antibody but it has severely reduced binding to all 
other serotypes (Figure 3). 
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Since the antibody H2 loop is predicted to interact with DenV1 and DenV3 
but not DenV2 and DenV4, we designed the H-S52A mutant to prevent 
antibody binding to DenV1 and DenV3 while leaving the other two serotypes 
unaltered (Figure 3). This mutant agrees with the computational prediction 
that the antibody uses different binding modes to interact with the serotypes as 
illustrated in Figure 2c. 
 
Rational Antibody Engineering to Improve the 
Neutralization Properties 
The aforementioned mutations are a testimony to our ability to rationally alter 
the antibody binding properties and specificity. Improving the ability of 
therapeutic products to protect from infection is, however, the main goal of 
antibody engineering. As a proof of concept, analysis of the predicted 
antibody/antigen interfaces allowed us to design a mutated antibody 40 times 
more efficient than the wild-type in neutralizing DenV1 and another mutant 




Fig. 43 We designed two antibody mutants with the intent of improving its 
neutralization properties. H-S52D (gray) neutralizes DenV1 40 times more 
efficiently than the wild-type (black) and L-N27E (violet) is better than the 
wild-type in all serotypes, albeit to a lesser extent. Viral neutralization assays 
are shown; the amount of infected cells (y axis) decreases at increasing 
antibody concentration (x axis). In comparison to the wild-type, a lower 
concentration of mutants is required to neutralize the same amount of virus. 
 
Our models show that H-S52 is in close proximity to a positively charged 
lysine sidechain in DenV1 (Figure 5).  
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Introducing a nearby negative charge should favor the formation of 
intermolecular salt bridges, possibly resulting in improved neutralization 
properties. Indeed, the H-S52D antibody is 40 times more efficient in 
neutralizing DenV1; the estimated antibody concentration required to achieve 
50% neutralization (EC50) is 0.1 mg/ml for HS52D and 4.1mg/ml for wild-
type DV32.6 (Figure 43).  
SPR indicates that the koff is identical to the wild-type while the kon improves 
from 0.95±0.01x10-4 to 4.8±0.4x10-4 nM-1s-1 resulting in a KD of 28±2 nM 
versus 145±9 nM. DenV4, where H-S52D is also a slightly better neutralizer 
than the wild-type, has a similar improvement in kon (1.5±0.1x10-4 for the 
wild-type,5.3±1.0x10-4 nM-1s- for H-S52D) and the koff improves as well (from 
5.1±1.3x10-3 to 0.47±0.1x10-3 s-1) resulting in KD of 0.9±0.04 nM for the 
mutant versus 34±7 nM for the original antibody. L-N27, instead, is predicted 
to be close to a positively charged region in all serotypes (Figure 44) so 






Fig. 44 a) H-S52 is close to the positive sidechain of K400 in DenV1. 
Mutating it to the negatively charged H-S52D favours the interaction and this 
mutant is 40 fold more effective than the wild type at neutralizing DenV1. The 
antibody is shown in green and Denv1 in blue.  
b) DV32.6 is shown as green cartoon over the electrostatic surface of DenV3; 
positively charged surfaces are in blue and negatively charged surfaces in red. 
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L-N27 is close to a positive patch conserved in all serotypes. Introducing a 
negative charge (L-N27E) favours the interaction, resulting in improved 
neutralization properties. The L-N27E substitution was preferred to L-N27D 
since the longer sidechain was thought to bring the charged antibody moiety 
closer to DIII. 
 
An N>E rather than N>D mutation was introduced because a longer side chain 
would get closer to the antigen without creating clashes, according to the 
models. Indeed, the L-N27E mutant has improved neutralization properties for 
all serotypes (Figure 43).  
The L-N27E mutant is 3 times more effective on DenV1, 6 on DenV2, 9 on 
DenV3 and 17 on DenV4 (ratios between the EC50 for wild-type and mutant 
antibody). KD is 5 times stronger for DenV1, 23 times stronger for DenV2, 4 
times for DenV3 and 38 times for DenV4. The mutant has improved Kon in all 
serotypes whereas the Koff is equal to the wild type for DenV1 and DenV3. 
Unfortunately, the effects of the H-S52D and L-N27E mutations are not 
additive; the double mutant shows better neutralization only for DenV3. 
Apparently, the interaction cannot tolerate the simultaneous introduction of 




The test case that has been performed using a known X-ray structure of a 
complex between DIII of DENV2 and the antibody 1A1D demonstrates that 
docking is able to give us the correct solution, but relying only on the scoring 
function makes it impossible to discriminate the right solution amongst the 
thousands of wrong ones. 
Here we utilized NMR chemical shift mapping  to identify the epitope of an 
antibody isolate from a Dengue patient, called DV32.6, on DIII of 
DENV4.DV32.6 binds the whole virus, the full E protein dimer and DIII 
alone in all four dengue serotypes but it can not neutralize DENV4 and only 
weakly neutralizes the other serotypes, showing also a significant ADE 
activity. 
According to our NMR epitope mapping experiment, applied for the first time 
to the characterization of a full size human mAb, there are twenty-six residues 
of DENV4/DIII that show significant chemical shift perturbation upon 
formation of the complex, defining the epitope region. We then performed the 
docking simulations to obtain information about the antibody residues 
implicated in the binding and about the orientation of the two partners of 
interaction. Models with a good scores are analyzed to check their agreement 
to the experimental data both by visual inspection, initially, and also at a finer 
and more quantitative level by using two indicators that we developed 
specifically for the task. The validity of such indicators was tested on a TCR-





The docking simulation was performed for each of the eleven different 
antibody structures independently obtaining an ensemble of decoys. These are 
filtered according to the above-mentioned criteria and only the models that are 
in agreement with the experimental data are kept. This approach allows us to 
take in account the conformational flexibility of the CDR loops of the 
antibody, especially of H3, into the docking search, considerably improving 
the accuracy of the result. 
The same procedure was performed for the DV32.6-DENV1 interaction. 
According to the chemical shift mapping experiment, the epitope residues are 
almost the same of DENV4 but comparing the structures of the two 
complexes shows a different binding orientation of the antibody. Analyzing 
the results in the context of the full E protein dimer, which forms the viral 
surface, the epitope on DENV1 is more accessible than that of DENV4. 
Considering that, according to our neutralization assays, DV32.6 is capable of 
neutralizing DENV1 but not DENV4 despite a stronger binding to DENV4-
DIII, we can speculate that this is due to the partial occlusion of the DENV4 
epitope by the other domains of the E protein. 
Moreover strategies for optimizing and improving antibody properties are 
highly desirable, either to increase their efficacy or to alter their binding 
specificity. Generally speaking, abolishing or altering antibody binding to 
undesired antigens might confer selectivity to an otherwise broadly reactive 
antibody, with practical uses in avoiding cross-reactivity or designing specific 
biomarkers. Here we move further ahead by showing that computational 
models of antibody/antigen complexes allowed us to rationally design 
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antibody mutants that improve its properties by i) disrupting binding only to 
selected serotypes and ii) improving virus neutralization up to 40 fold. 
Antibody DV32.6, isolated from the serum of a human donor recovered from 
DenV2 infection, can efficiently neutralize three of the four DenV serotypes 
but binds to all four in the so-called DIII, the most variable domain of the 
protein forming the viral surface and the target of many potent antibodies 
described so far. We identified the epitope of DV32.6 on each serotype at the 
residue level with solution NMR spectroscopy and used this information to 
guide and validate computational docking simulations yielding three-
dimensional models of the antibody/antigen complexes. Visual analysis of 
these NMR validated computational structures allowed us to design a total of 
22 antibody mutants, only 4 of which did not have the predicted effect. With 
this approach we produced DV32.6 antibody mutants that could a) leave 
binding unaltered, proving that we can identify residues that are not critical 
for interaction despite belonging to the antigen binding loops or b) abolish 
binding to all serotypes. More importantly, whereas wild-type DV32.6 binds 
to all four DenV serotypes, we could design antibody mutants binding only to 
DenV2 or to DenV2 and DenV4. Increasing antibody specificity is valuable to 
eliminate unwanted cross-reactivity or to design bio-recognition elements. If 
an antibody has therapeutic purposes, however, one would seek to improve its 
neutralization properties, which would have a beneficial effect on dosage and 
therapy. 
In conclusion, we demonstrated that computational docking is a fast and 
accurate tool to obtain the structure of antibody/antigen complexes, provided 
that it is validated by rapidly obtained experimental data. The use of NMR 
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epitope mapping, a fast and reliable technique to identify antibodies epitopes, 






Solution NMR spectroscopy is ideally suited to the characterization of 
intermolecular interfaces, including antibody/antigen complexes. NMR 
chemical shift mapping provides a detailed description of the binding footprint 
of one molecule over another. 
The results of NMR epitope mapping were used to greatly increase the 
accuracy of computational docking, providing a three-dimensional atomic 
structure of the protein/protein and antibody/antigen complex. Roughly 
speaking, information on the NMR-derived epitope is either used as a 
constraint to guide the structure calculation algorithm30,150,151, possibly with 
other information that can help orientate the components of a multimolecular 
complex152, or at the end of the computational simulation to filter out models 
that do not agree with the experimental epitope34,35. In the antibody/antigen 
interaction the resulting structures were sufficiently accurate to allow rational 
modifications of an antibody, altering its selectivity and increasing its viral 
neutralization properties by up to 40 folds36. On the other hand, the NMR 
mapping used to drive computational docking was useful to hypnotize   the 
structural conformation of CXCL12/HMGB1 complex in the cellular response 
triggering. Although Xray is obviously better at structure determination, NMR 
mapping offers comparable results in a fraction of the time for epitope 
characterization. 
Once NMR assignments are available for the antigen or general proteins, 
several different partners can be rapidly mapped, typically requiring few days. 
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NMR epitope mapping also has a clear advantage over peptide mapping and 
site-directed mutagenesis, because it provides a complete description of the 
antigen residues contacted by the antibody which is very difficult to obtain by 
these other techniques. The disadvantages of NMR epitope mapping include 
the fact that the antigen or in this case chemokines needs to be labeled with 
NMR active nuclei (typically 15N). It is thus necessary to express the antigen 
in Escherichia coli (more seldom yeast), which is not always possible. 
Furthermore, large antigens present a challenge for NMR due to both spectral 
overlap and signal broadening at increased molecular weight leading to loss of 
sensitivity. Selective labeling of specific antigen residues, advanced 
acquisition techniques such as TROSY and the use of 15N-HSQCs, probably 
the simplest and most sensitive multidimensional NMR experiment, somehow 
alleviate these limitations, which nonetheless remain significant in some 
cases. Finally, NMR assignment of the antigen, that is, knowing which NMR 
signal corresponds to which antigen residue, is necessary. Assignment can be 
a trivial process of a few days or a difficult task requiring several months and 
complex strategies for selective labeling.  
NMR epitope mapping is a rapid and accurate tool for the characterization of 
antibody/antigen or protein/protein complexes. So far, there are relatively few 
examples of using high-resolution NMR spectroscopy to determine antibody 
epitopes, and most involve small peptides rather than full protein 
antigens35,36,37,38,39,42,153, but NMR epitope mapping is a valuable tool for the 




Material and methods 
Protein production and purification 
15N-labeled CXCL12 was obtained by growing Escherichia coli Rosetta cells 
transfected with pET30 vector, in which the CXCL12 sequence was cloned, in 
M9 minimal media containing 15N- ammonium chloride., The cells were 
induced at OD600=0.6 and harvested after 4 hours. The pellet was put for at 
least 1 hour at -20 °C. The cells were thawed and resuspended in 50 mM 
TrisHCl pH8, 100 mM NaCl; 1 mM EDTA 5 mM DTT and 0.1% Triton 
X100. After sonication and centrifugation, the pellet was repeatedly washed 
and centrifuged with  50 mM TrisHCl pH8, 100 mM NaCl; 1 mM EDTA 5 
mM DTT and 0.1% Triton X100.  and subsequently solubilized in 50 mM 
MES pH 6.5 and 6 M guanidinium HCl overnight at 37 °C. Afterwards 
CXCL12 was refolded by dilution in 50 mM TrisHCl pH8, 50 mM NaCl, 0.1 
mM reduced glutathione and 0.1 mM oxidized glutathione, overnight at 4°C. 
CXCL12 was then loaded on SP Cation exchange column and finally passed 
in Size exclusion column Superdex75 pre-equilibrated with20 mM NaP pH6 
,20 mM NaCl. 
15N-labeled BoxB was obtained by growing Escherichia coli Rosetta cells 
transfected with pET30 vector in which the BoxB sequence was cloned, in M9 
minimal media containing 15N- ammonium chloride. The cells were induced 
at OD600=0.8-0.9 and harvested after overnight growing. The pellet was put 
for at least 1 hour at -20 °C. The cells were thawed and resuspended in 20 mM 
TrisHCl pH8, 10 mM imidazole, 2 mM 2-ȕ-mercaptoethanol, 150 mM NaCl. 
After sonication and centrifugation, the supernatant was loaded on Hitrap 
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Chelating HP column; after the loading 2 washing steps with increasing 
concentration of imidazole were performed and BoxB was eluted with 300 
mM of imidazole. The protein was then dialyzed to remove the imidazole and 
passed on the size exclusion Superdex75 column pre-equilibrated in 20 mM 
NaP pH6 and 20 mM NaCl.  
HMGB1 was obtained by growing Escherichia coli Rosetta cells transfected 
with pET30 vector, in which the HMGB1 sequence was cloned, in M9 
minimal media containing 15N- ammonium chloride., The cells were induced 
at OD600=0.7 and harvested after 3h. The pellet was put for at least 1 hour at -
20 °C. The cells were thawed and resuspended in 20 mM TrisHCl pH8, 10 
mM imidazole, 2 mM 2-ȕ-mercaptoethanol, 150 mM NaCl, 0.2% triton X100. 
After sonication and centrifugation, the supernatant was loaded on Hitrap 
Chelating HP column ; after the loading3 washing steps with increasing 
concentration of imidazole were performed and HMGB1 was eluted with 300 
mM of imidazole. The protein was then dialyzed to remove the imidazole and 
passed on the size exclusion Superdex75 column pre-equilibrated with 20mM 












Transformation of Rosetta cells 
 
Used 150 ȝL of competent cells for transformation. 
 
De-ice competent cells. 
 






Incubate for some minutes on ice. 
 
Add 600 ȝ/RI/%DQGLQFXEDWHDWÛ&IRUK 
 









Starting from single colony pre-colture in 50 mL LB + KAN (30 









Used the pre-colture to inoculate 1 L of LB + KAN + CHO; starting 

















After 3 h the cells were collected by centrifugation (6000 rpm for 20 
PLQDWÛ& 
 







5HVXVSHQG WKH SHOOHW LQWR WKH DSSURSULDWH YROXPH %焀  P/ IRU J RI
cells) of LYSIS BUFFER (20 mM TrisHCl pH 8; 150 mM NaCl; 10 
mM Imidazole; 2 ȕ-SH; 0.2% Triton X100). 
 
Sonication: 30 sec of pulsing/30 sec of pause for 4-5 times 
Centrifuge at 18000 rpm for 30 min at 4 °C (rotor ss-34); keep the 
pellet (keep the SN for SDS Page) 
 
Hitrap Chelating Purification (Nickel column) 
Filter the SN and load on Hitrap Chelating HP column (GE 
Healthcare 5 mL volume) pre-equilibrated in lysis buffer. 
After loading wash as follow: 
- Wash 1: lysis buffer ± (20 mM TrisHCl pH 8; 150 mM NaCl; 10 mM 
Imidazole; 2 ȕ-SH) 
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- Wash 2: wash 2 buffer (20 mM TrisHCl pH 8; 1M NaCl; 10 mM 
Imidazole; 2 ȕ-SH) 
- Wash 3: wash 3 buffer (20 mM TrisHCl pH 8; 150 mM NaCl; 30 
mM Imidazole; 2 ȕ-SH) 
After the washing steps elute the protein with elution buffer (20 mM 
TrisHCl pH 8; 150 mM NaCl; 300 mM Imidazole; 2 ȕ-SH) 
 
Collected the fractions of the last peak (after 300 mM imidazole) 
Put in dialysis ON (1 L + 1 L) dialysis buffer 20 mM TrisHCl pH 8; 




The dialyzed sample was loaded on SE75 HiLoad pre-equilibrated 
with 20 mM TrisHCl pH 8; 20 mM NaCl; 2 ȕ-SH. 
 
According to the column specification, the peak corresponding to 
HMGB1 molecular weight is around 60 mL. 
 
LPS purification 
To remove LPS load your purify HMGB1 on an Anion Exchange (Q) 
column. 
Loading buffer: 20 mM NaP pH7.2; 20 mM NaCl 
Elution buffer: PBS pH 7.2+1.5M NaCl 
 







BoxA and BoxB purification; schematic practical 
protocol 
 
Transformation of Rosetta cells 
 
Used 150 ȝL of competent cells for transformation. 
 
De-ice competent cells. 
 










Centrifuge for 10 min at 4000 rpm 
 
Discard DERXWȝL of supernatant (SN), resuspend the pellet in the 
remaining LB and plate on LB + KAN + CHO (~50-ȝL)  
 























Used the pre-colture to inoculate 2 flasks of 2 L containing 500 mL of 
M9 + KAN + CHO.  






OD600 :  0.8-0.9 
 
 







After ON the cells were collected by centrifugation (6000 rpm for 20 
PLQDWÛ& 
 
Amount of cells:  about 7 gr 
 
















5HVXVSHQGWKHSHOOHW%焀 J into 20 mL of LYSIS BUFFER 
Lysis buffer  
20 mM Tris-HCl pH 8 
10 mM imidazole pH 8 
2 P0ȕ-Mercapto 
150 mM of NaCl 
 0.2% Triton 
 DNAse 
 
SONICATION: 30 sec of pulsing/30 sec of pause for 4-5 times 
Centrifuge at 40000 rpm for 30 min at 4 °C or 18000 for 1h, 4°C; 
keep the SN and filter it. 
 
Hitrap Chelating purification  
 
Column: Hitrap Chelating HP 5 mL (GE Healthcare) 
Load on the 5 mL column maximum 60 mg of protein 
 
 
Equilibrate the column with H2O (20 mL) 
 
Load 0.1 M NiSO4 (10 mL) 
 
Equilibrate the column with ATTACH BUFFER (until the UV is 
stable). 
 
Load the sample and collect the flow-through. 
 
Wait until the UV is stable and then wash the column with WASH 1 
and collect the flow-through.  
 
Wait until the UV is stable and then wash the column with WASH 2 




Wait until the UV is stable and then elute with ELUTION BUFFER 
and collect fractions. 
 
Measure all the fractions and the flow-through with Nanodrop. 
 




20 mM Tris-HCl pH 8 
10 mM imidazole pH 8 
2 mM 2-E-mecaptoethanol 
150 mM NaCl 
 
Wash 1 
20 mM Tris-HCl pH 8 
10 mM imidazole pH 8 
2 mM 2-E-mecaptoethanol  
1 M NaCl 
 
Wash 2 
20 mM Tris-HCl pH 8 
30 mM imidazole pH 8 
2 mM 2-E-mecaptoethanol  
150 mM NaCl 
 
Elution buffer 
20 mM Tris-HCl pH 8 
300 mM imidazole pH 8 
2 mM 2-E-mecaptoethanol  
150 mM NaCl 
 
The fractions pulled (i.e. B7/B6 ;3 ml+3 ml) were diluted  until 20 ml 
with the Elution Buffer without imidazole and after concentrate until 







Size exclusion chromatography 
 
Column: Hiload Superdex75 (GE Healthcare); column volume 
about 125 mL 
Load on the column maximum 3 mL of protein 






DenV DIII purification; schematic practical protocol 
 
- PROTEIN EXPRESSION 
- Transform Rosetta cells (DE3) with DIII plasmid and perform eat-
shock protocol (30 sec @ 42 °C and 2 min in ice. Add SOC media and 
leave @ 37 °C for 1 h. 
- Place the cells in LB plate + Amp + CHA and grow O.N. 
- Grow cells @ 37 °C until the O.D.600 is around 0.6-0.8 and then 
induce with 0.5 mM IPTG. 
- After induction grow @ 37°C for 4 hs, then collect the  cells with a 




- PROTEIN EXTRACTION 
(set the centrifuge @ 4°C!!) 
(tube in ice!!!) 




- WASHING: resuspend the pellet into 25-30 mL of washing buffer 
(20mM Na phos pH7.5 + 150mM NaCl  + 1M urea + 1% Triton) and 
FHQWULIXJH#USPIRU¶ 
- Resuspend the pellet into 35 mL of solubilization buffer (20mM Na 
Phos  + 8M urea + 1M NaCl) 
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- Stir @ 37°C O.N. 
 




- Keep the supernatant 
 
- REMOVE PEI WITH AMMONIUM SULFATE (AS) 
 
- Add 65% of A.S. and leave 1h 
- &HQWULIXJHUSPIRU¶#&DQGNHHSWKHSHOOHW 
- Resuspend the pellet into 8M urea + 20mM Na phos  
 
- REFOLDING 
Refolding by dilution in 20 mM NaP pH 7.5; 100 mM NaCl; 200 mM  
arginine; 1 mM Glutathione Red; 0.1 mM Glutathione Ox (final pH 
about 10) . 
Recommended final protein concentration: 0.1 mg/mL 
Keep the sample Overnight at 4 °C without stirring. 
 
 Size Exclusion Chromatography  
Filter the samples, then concentrate with Vivaspin Sartorius 
concentrators; initial speed 2300g then switch to 1600g at smaller 
volumes; temperature 8 °C. 




NMR epitope mapping 
NMR chemical shift mapping were conducted in order to identify the CXCL12 
residues affected by the binding with the full HMGB1 and also with its 
domains separately, BoxA and  BoxB. The NMR experiment was also 
performed on the complex between 15N labeled BoxB and CXCL12. 
 15N-HSQC experiments were performed on a Bruker 700-MHz spectrometer 
with CryoProbe. Acquisition time varied between 30 min (for free CXCL12 
and  BoxB) and 16 h (for the complexes). An HSQC spectrum was recorded on 
the free, labeled component; a second HSQC was recorded after addition of the 
unlabeled partner (1:1 ration for the CXCL12/BoxB or BoxA complexes; 2:1 
for CXCL12/HMGB1). Backbone assignments were obtained by comparison 
to previously published data (Biological Magnetic Resonance Bank accession 
numbers 15148, 15149, and 16145). 
Residues whose NMR signal changes position upon complex formation were 
identified by visual comparison of free and bound spectra of CXCL12 or BoxB 
in complex with partners. For quantitative analysis, the amount of chemical 
shift change upon complex formation was calculated for each residues 
according to the formula ඥሺ ?ܰ  ?  ?Ǥ ?ሻଶ ൅   ?ܪଶ  ZKHUH ǻN DQG ǻH are the 
chemical shift difference between free and bound spectrum in the nitrogen and 
proton dimension. 
 
Surface Plasmon Resonance binding assays 
Surface Plasmon Resonance (SPR) is a powerful, label-free technique to 
measure biomolecular interactions in real-time. One of the two partners under 
study is immobilized to the sensor surface, usually covered with a gold layer, 
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the other molecule is free in solution and flowed over the surface. Association 
and dissociation parameters are measured and displayed in a graph called 
sensorgram (figure 28). Subsequent data analysis allows: 
x confirming the binding of two or more partners to each other 
x determining the binding affinity of the interactions 
x measuring  the association and dissociation rates. 
SPR-based instruments use an optical method to measure the refractive index 
near (within ~300 nm) the sensor surface, usually a gold surface. Gold is used 
because it gives a SPR signal at convenient combinations of reflectance angle 
and wavelength and, in addition, is chemically inert to solutions and solutes 
typically used in biochemical contexts. The binding partner (analyte) is 
injected under continuous flow in aqueous solution (sample buffer) through the 
flow cell. As the analyte binds to the ligand the accumulation of protein on the 
surface results in an increase in the refractive index, altering the reflection of 
the laser light beam sent on the chip. This change in refractive index is 
measured in real time, and the result plotted as response or resonance units 
(RUs) versus time (sensorgram).  
The sensor chip of the Bio-Rad Proteon-XPR36, used in our experiments, is 
formed by six parallel channels thus up to six ligand can be immobilized in a 





Figure 45: Representation of Bio-Rad Proteon-XPR36 SPR chip surface, the 
ligand immobilization and analyte injection create a 6x6 ligand-analyte 
interaction array, and schematic view of the physical process leading to the 
sensorgram graph. 
 
Immobilization of the ligand to the sensor surface must, of course, happen 
without disrupting its activity. Several chemical strategies for immobilization 
are available, the most common for biomolecules involving covalent coupling 
between carboxyl groups on the sensor surface and amines in the protein 
ligand. 
Amine coupling requires two main steps. Firstly EDAC (1-Ethyl-3-[3-
dimethylaminopropyl] carbodimide hydrochloride) reacts with the carboxyl 
groups on the chip surface forming an amine-reactive intermediate; in the 
second step the addition of Sulfo-NHS stabilizes the intermediate by 
converting it to an amine-reactive Sulfo-NHS ester that can form a stable 
amide-bond to amine groups in the ligand protein (typically lysines). The 
immobilization is concluded with a blocking step, where a high concentration 
of ethanolamine is injected to block the remaining activated carboxymethyl 
groups and prevent further covalent interaction between the surfaces and 
protein ligands subsequently added over the chip.  
Immobilization is followed by the interaction phase. The analyte diluted in the 
sample buffer is injected into another set of six parallel channels, orthogonal to 
the six ligand channels, to create a 6x6 ligand-analyte interaction array. Six set 
of six sensorgram are rapidly generated in a single analyte injection step. 
Detailed kinetic data can be obtained from these sensorgrams on the interaction 




All the SPR experiments were conducted at 25 °C with Bio-Rad Proteon-
XPR36. 
The first experiment has been performed to set up the best binding condition 
for CXCL12/HMGB1. In three of the six vertical channels HMGB1 250 nm in 
oxidated and reduced states were immobilized, in two of these CXCL12 was 
immobilized and the last one was empty in order to appreciate the unspecific 
binding effect. The blocking solution was used in order to block the remaining 
activated carboxymethyl groups. Afterword the SPR system injected the 
analyte using the six horizontal channels. In the horizontal direction 5 
concentration of CXCL12 have been injected   (750, 500, 250 and 100 nM) 
diluted in three different Buffers with different pH.  Phoshate Buffer pH6, 
Na2HPO4 Buffer pH 11 and NaAc pH 4.5 promoting CXCL12 in monomeric 
conformation, the sixth channel was empty. In the sixth channel is possible 
appreciate the large contribution coming from the unspecific binding, that 
GRHVQ¶W JLYH WKH SRVVLELOLW\ WR HVWLPDWH WKH ELQGLQJ FRQVWDQW 2WKHUZLVH WKH
experiments showed the concentration dependent binding process, indeed the 
sensorgram signal increase with the increasing of CXCL12 concentration. 
In the second experiment, glycyrrhizin was flowed over the surface at 
concentrations of 0, 500, or 5,000 nM, followed by the addition of 500 nM 
CXCL12. CXCL12 binding to HMGB1 was detected in all cases, but the signal 
intensity decreased at increasing concentrations of glycyrrhizin. The 
experiment was conducted at pH 6.0 in 20 mM Na phosphate buffer and 20 
mM NaCl. Several reference channels were used, either flowing CXCL12 and 
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glycyrrhizin over a sensor surface in the absence of HMGB1 or flowing buffer 
without CXCL12 or glycyrrhizin over a surface with immobilized HMGB1. 
 





Computational docking simulation was performed using RosettaDock 2.3 as 
previously described (Ref to JMB and PlosOne). The publically available 
experimental structures of CXCL12 (PDBid: 2kee) and HMGB1 (PDBid: 2yrq) 
were used for docking. The starting structures were visually oriented and then 
separated by 25 Å.  
The CXCL12 was docked separately with BoxA and BoxB. The HMGB1 
domains were kept fixed while CXCL12 was brought towards them with 3-8-8 
perturbations [perturbations along the line of centers (in angstroms) ± 
perturbation in the plane perpendicular to the line of center (in angstroms) ± 
rotational perturbation (in degrees)].  
After each docking run we obtained a total of 20,000 decoys. The lowest 
scoring models were visually analyzed and the decoys in accordance with the 
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